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ABSTRACT OF THE DISSERTATION 
FACTORS OF INFLAMMATION IN HAITIAN AMERICANS AND AFRICAN 
AMERICANS WITH AND WITHOUT TYPE 2 DIABETES 
by 
Janet Antwi 
Florida International University, 2014 
Miami, Florida 
Professor Fatma G. Huffman, Major Professor 
Chronic low-grade inflammation has been implicated in the processes leading to 
the development of type 2 diabetes (T2D) and its progression. Non-Hispanic Blacks bear 
a disproportionate burden of T2D and are highly susceptible to inflammation. This cross-
sectional study assessed and compared the serum levels of established adipocytokines; 
interleukin-6 (IL-6), C-reactive protein (CRP), leptin, and novel adipocytokines; 
chemerin and omentin in Haitian and African Americans with and without T2D. The 
relationships of these adipocytokines with metabolic syndrome (MetS), anthropometric 
and HOMA2 measures by ethnicity and diabetes status were also assessed. Serum levels 
of IL-6, CRP, leptin, chemerin and omentin were determined by the ELISA method. 
HOMA2 measures were calculated for insulin sensitivity (HOMA2-IS) and insulin 
resistance (HOMA2-IR). 
Analyses of available data for 230 Haitian Americans and 241 African Americans 
(240 with and 231 without T2D) for the first study showed that Haitian Americans with 
and without MetS had lower levels of IL-6 and CRP compared to African Americans 
with and without MetS (P<0.05). MetS was found to be associated with CRP (β = 0.34, P 
vi 
 
= 0.012), but not with IL-6. In the second study (n = 429), Haitian Americans with T2D 
had significantly lower serum chemerin levels (P <0.001) and higher serum omentin 
levels (P = 0.023) compared to African Americans with T2D. Diabetes status was 
negatively associated with chemerin (B = -41.35, P = 0.024), but not associated with 
omentin (B = -85.02, P = 0.136). HOMA2-IS was inversely associated with chemerin (B 
= -0.229, P = 0.030). Leptin levels in the third study (n= 413) were lower in Haitian 
American males and females than African American males and females, regardless of 
diabetes status (P<0.05). Leptin levels were significantly associated with BMI (P<0.001) 
and HOMA2-IR (P=0.015) in males without T2D. 
Ethnic-specific diabetes intervention and treatment programs must be designed to 
target Haitian Americans and African Americans as separate unique groups, in order to 
reduce the burden of T2D among the non-Hispanic Black community. Further research is 
needed to gain better understanding of the role of inflammation and T2D in this 
population.   
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CHAPTER I: INTRODUCTION 
Type 2 diabetes (T2D) is a major public health concern among ethnic minority 
groups in the United States and non-Hispanic Blacks in particular, are disproportionately 
affected.1-3 The disparities in the incidence and prevalence of T2D among non-Hispanic 
Blacks are estimated to be 2 to 6 times of that observed in Caucasians.2,4 While reasons 
for these disparities have not been fully understood, increased prevalence of disease risk 
factors among this population are considered as the cause.5-6 One such risk factor which 
is receiving increased attention is inflammatory processes, since T2D is considered to be 
a state of chronic low-grade inflammation.7 
Chronic low-grade inflammation, as characterized by increased circulating levels 
of pro-inflammatory adipocytokines, is a key feature of chronic diseases including 
obesity, T2D and cardiovascular diseases (CVD).8-10 Several studies have associated 
plasma levels of pro-inflammatory adipocytokines such as tumor necrosis factor-α (TNF-
α), interleukin-6 (IL-6), C reactive protein (CRP) and leptin with metabolic risk factors 
such as obesity and insulin resistance.13-14 The levels of the anti-inflammatory 
adipocytokine, adiponectin are however reduced in these disease conditions.15-17 Similar 
observations have also been made between these markers and metabolic syndrome 
(MetS) in individuals with and without T2D.8,18 
Previous studies that found an association between inflammation and the 
pathogenesis and progression of T2D also reported on ethnic differences in the levels of 
established adipocytokines such as, TNF-α, IL-6, CRP, leptin and adiponectin.5-6,19 
Chemerin and omentin are recently identified novel adipocytokines that have been shown 
to have reciprocal effects in inflammatory processes and chronic disorders.20-22 The levels 
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of pro-inflammatory chemerin are increased in obesity, insulin resistance, metabolic 
syndrome, T2D and cardiovascular diseases, while the anti-inflammatory omentin is 
down-regulated in these disorders.23-27  
In a recent study, BMI, fasting serum insulin, triglycerides and high density 
lipoprotein cholesterol (HDL-C) were significantly correlated with plasma chemerin 
levels in 969 Mexican-Americans with T2D compared to 173 without T2D.28 Similar 
relationships have been observed in various other populations.23,29 However, the roles of 
chemerin and omentin as novel candidates to link inflammation with T2D in other ethnic 
minority subgroups such as Haitian and African Americans have not been studied. 
Furthermore, recent studies have associated chemerin and omentin with several 
established pro-inflammatory and anti-inflammatory adipocytokines,24,26 but data on their 
interactions among Haitian and African Americans is scarce. The study of novel 
adipocytokines may provide better understanding of the disparities in T2D that exist 
among non-Hispanic Blacks. 
Therefore, the aims of this study were to characterize adipocytokines in Haitian 
and African Americans with and without T2D and determine the relationships of these 
adipocytokines with metabolic syndrome (MetS), anthropometric and HOMA2 measures 
by ethnicity and diabetes status controlling for socio-demographic variables, dietary and 
lifestyle factors and other health status variables.   
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CHAPTER II: LITERATURE REVIEW 
Diabetes is a metabolic disorder that has emerged as a global epidemic and is 
estimated to be the seventh leading cause of death by the year 2030.1 According to 
estimates by the World Health Organization, as of 2011, there were approximately 347 
million people with diabetes worldwide.1 In the United States, an estimated 29 million 
people have diabetes, of which 90-95% of cases are attributed to type 2 diabetes (T2D).2 
The burden of T2D is increasing in parallel to increasing cases of obesity and metabolic 
syndrome (MetS).3 Clinical data show that of the people diagnosed with T2D, about 80-
90% are highly likely to be diagnosed as obese.4 Mozumdar and Liguori3 compared the 
National Health and Nutrition Examination Survey (NHANES) data from 1988-1994 and 
1999-2006 and revealed that there was a 5% increase in MetS prevalence among US 
adults between the two periods. The authors also reported that Mexican-Americans had 
the highest prevalence of MetS and there was a significant increase in prevalence among 
non-Hispanic Blacks compared with non-Hispanic Whites.  
 Non-Hispanic Blacks are particularly at a greater risk of T2D and its 
complications compared to Hispanics and Non-Hispanic Whites.5-8 Apart from higher 
prevalence rates of T2D, ethnic minority groups also have poorer diabetes control and 
worse diabetes-related complications. Lanting et al.7 examined ethnic differences in 
quality of care, end-stage complications and mortality among patients with diabetes. The 
results showed that non-Hispanic Blacks and Hispanics have 2 to 4 times the rate of 
blindness, kidney disease and amputation-related mortality of non-Hispanic Whites. 
Diabetes data and trends for 2010, available at the Centers for Disease Control and 
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Prevention indicated that diabetes-related heart disease and myocardial infarction was 
34% in non-Hispanic Blacks, 24.7% in Hispanics and 32.9% in non-Hispanic Whites.5  
Compelling evidence from recent studies suggest that observed ethnic differences 
in inflammation may provide major explanation to the disparities in T2D prevalence and 
health outcomes.9-11 Various analyses of the association between ethnicity and 
inflammation showed that non-Hispanic Blacks have higher IL-6 and CRP than 
Hispanics and non-Hispanic Whites. Further, TNF-α levels were higher among non-
Hispanic Blacks compared to non-Hispanic Whites.12 There is the need to understand the 
molecular mechanisms that underlie inflammatory processes to relate to their pathogenic 
role in metabolic disease development in order to establish strategies to effectively 
combat T2D and its complications among non-Hispanic Blacks. 
Chronic Low-grade Inflammation 
 Inflammation is a complex defense mechanism induced by the body to various 
injuries and foreign stimuli.13-15 The process of inflammation is a normal immune 
response, which may be innate or adaptive. This often self-regulatory and short-term 
response is a crucial part of tissue repair and involves the combination of several complex 
signals in particular cells and organs.15 The presence of an injury or stimuli initiates the 
migration of leucocytes (mainly neutrophils) from circulation into the affected tissues to 
attack the agents that possibly can cause tissue injury.14,16 Neutrophils secrete pro-
inflammatory cytokines including tumor necrosis factor-alpha (TNF-α) and interleukin-6 
(IL-6) to induce an immune response and return the body to a homeostatic state.17-19 
Additionally, IL-6 in particular, stimulates production of the acute-phase reactant, C-
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reactive protein (CRP) from the liver.20-21 This form of inflammatory response referred to 
as acute inflammation is actively terminated within the first few hours of inflammatory 
response.22 The resolution of inflammation involves mainly eliminating neutrophils by 
the phagocytic and destructive actions of monocytes and macrophages and also through 
the release of anti-inflammatory cytokines such as IL-10.22-23 Thus, acute inflammation is 
considered as a limited, often beneficial response. However, in the presence of an 
ongoing stimuli, the immune response may be persistently triggered and lead to chronic 
low-grade inflammation. 
Chronic low-grade inflammation, in contrast to acute inflammation is associated 
with infiltration of mainly monocytes and macrophages of the immune response.14,16 
Chronic low-grade inflammation is considered as a chronic activation of the innate 
immune system than the adaptive.24 The mechanisms that control the transition from 
neutrophil to monocyte/macrophage recruitment during the transformation from acute to 
chronic inflammation is poorly understood. However, the body’s own process used to 
resolve inflammation, whereby monocytes/macrophages or fibroblasts are recruited to 
phagocytize neutrophils has been implicated.22,25 A disruption in control of neutrophils 
trafficking by a continuous stimuli, may cause the resolution phase to be disordered. This 
may be significant at increased recruitment of monocytes/macrophages and the 
overproduction of pro-inflammatory cytokines resulting in a perpetual pro-inflammatory 
state.22,25 The long-term consequences of this prolonged inflammation which favors the 
production of pro-inflammatory cytokines and decreased levels of anti-inflammatory 
cytokines are often detrimental.26-32 The hallmark of chronic low-grade inflammation is 
systemic inflammation, which is the involvement of the endothelial, circulatory, 
10 
 
lymphatic and other organs systems, rather than restricted to a specific tissue. As a result, 
chronic low-grade inflammation is characterized by 2 to 3 fold increase in circulating 
levels of TNF-α, IL-6 and CRP and decreased levels of IL-10.26 The altered circulating 
levels of these pro- and anti-inflammatory cytokines have been observed in various 
chronic diseases and it is suggested that chronic low-grade inflammation may be crucial 
in the pathogenesis and progression of chronic diseases.26-32 For example, the levels of 
circulating TNF-α, IL-6 and CRP have consistently correlated with obesity and insulin 
resistance and has provided the basis for an intense area of research into other metabolic 
disorders such as metabolic syndrome, type 2 diabetes and cardiovascular diseases.33-34 
The discovery of the adipose tissue as an endocrine organ is expected to provide better 
insight into the processes underlying the onset and progression of these metabolic 
conditions.  
Adipose Tissue as a Major Source of Adipocytokines 
For many decades, adipose tissue was considered as a fat storage organ and also 
known to possess thermogenic properties. In human and animal models, brown adipose 
tissue has been shown to be responsible for thermogenesis, whereas white adipose tissue 
plays the essential role of being a fat storage site.35 Recently, however, adipose tissue has 
been established as an active endocrine organ that produces several bioactive molecules 
collectively termed adipocytokines.36-40 They are so named because they are cytokines 
produced by the adipose tissue. The most abundant sites are visceral and subcutaneous 
adipose tissues,41 which produce bonafide adipocytokines such as leptin and adiponectin 
known to elicit pro-inflammatory and anti-inflammatory responses, respectively.42-43 
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Adipocytokines have diverse autocrine, panacrine and endocrine functions and as such 
are crucial mediators of metabolic processes including glucose and lipid homeostasis.41-42 
For example, leptin and adiponectin have the ability to cross the blood-brain barrier and 
reach their main site of action in the hypothalamus to regulate the balance of hunger and 
satiety.38 Thus, these adipocytokines play a major role in the control of energy 
metabolism, the nutrient status of the organism and energy expenditure.44 Several 
investigations have also highlighted the importance of TNF-α and IL-6, as 
adipocytokines which activate inflammatory signaling cascades in adipose tissue.33-34 The 
adipose tissue is known to produce about 10-35% of the body’s IL-6 levels.45 Moreover, 
in a recent  in vivo study, human adipocyte cell lines were found to have the capacity to 
also produce CRP.46 It is important to know the initiating factors responsible for 
induction of adipose tissue inflammation and the mechanism that continue to amplify the 
pro-inflammatory state. 
Chronic disruption of metabolic homeostasis, such as occurs in overnutrition 
could lead to irregular immune responses.47 In the presence of a continuous nutritional 
oversupply, excessive lipid accumulation in adipose tissues results in obesity.48 Since the 
bulk of accumulated lipid is stored in adipocytes, the excess nutrition overload causes 
adipocytes to rapidly proliferate and expand resulting in cellular stress.47-48 With excess 
adiposity, monocytes and macrophages are chronically recruited to adipose tissue which 
enhance the secretory capacity of adipose tissue and results in overproduction of pro-
inflammatory TNF-α, IL-6 and leptin and decreased production of anti-inflammatory, 
adiponectin.39,49 Consistent with the evidence of a link between the adipose tissue and 
inflammation, studies have shown serum levels of adiponectin to inversely correlate with 
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fatness, whereas the levels of TNF-α, IL-6, CRP and leptin increase with increasing 
adiposity.34,50 Thus, it is firmly established that obese individuals display a characteristic 
imbalance of their adipocytokine profile.50 The role of adipocytokines as modulators of 
whole body energy balance and inflammatory processes has been demonstrated in most 
clinical studies.51 Weight loss due to long-term caloric restriction was associated with 
reduced levels of pro-inflammatory adipocytokines and increased levels of anti-
inflammatory adipocytokines.51 However, some studies have also demonstrated that 
dysregulation of these adipocytokines may be observed under conditions associated with 
a lack of adipose tissue.52 This is with reference to individuals who though are lean, 
usually have increased levels of pro-inflammatory adipocytokines and develop MetS and 
T2D. It has been well-established that metabolic changes related to obesity are 
principally attributable to abdominal or visceral fat mass rather than subcutaneous fat 
mass.53 These fat masses vary by cell size, metabolic activity and potential role in 
inflammatory processes.54 Visceral fat, usually measured by waist circumference (WC) is 
more pathogenic.53-54 Thus, supposedly, lean individuals may have abnormal distribution 
of body fat with more stores in the visceral area.    
Adipose tissue function in inflammatory processes and the development of 
metabolic disorders in both human and animal systems is unprecedented and continues to 
expand. The works of Bazaoglu et al.55 and Yang et al.56 have led to the discovery of the 
novel adipocytokines chemerin and omentin. Chemerin is a recently discovered 
adipocytokine that is highly expressed in white adipose tissue and liver.55 It is a ligand 
activator for G-protein coupled receptor, chemokine-like receptor 1 (CMKLR1) and 
thought to modulate innate and adaptive immunity by binding to this receptor found on 
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immune cells.57-59 Importantly, chemerin has been shown to have effects on adipose 
tissue development, metabolism and inflammation in both human and animal 
adipocytes.60 Chemerin mediates inflammatory processes as it is a chemokine to promote 
the migration of macrophages and immature dendritic cells and adhesion of macrophages 
to the endothelium.57-61   
Yang et al.56 described omentin as a novel adipocytokine with insulin-sensitizing 
effects.  Omentin is a soluble galactofuranose-binding lectin preferentially expressed by 
visceral omental adipose tissue but not by subcutaneous adipose tissue.56,62  Omentin is 
recognized as an anti-inflammatory adipocytokine that has similar functions as 
adiponectin, and thus reduced in disorders involving inflammatory processes.63-66 
Moreover, omentin attenuated CRP and TNF-α induced nuclear factor kappa-B (NF-kB) 
activation in human endothelial cells.65  Because of the key role that adipocytokines play 
in the regulation of glucose and lipid metabolism, they have been suggested to provide 
the link between obesity, inflammation and impaired insulin signaling which lead to the 
development of obesity-related disorders including MetS and T2D. The association of 
chronic low-grade inflammation with insulin resistance is a growing area of research 
interest.  
Adipocytokines, Insulin Signaling and Insulin Resistance 
Insulin is a hormone secreted from the cells localized to the pancreatic β islets and 
is necessary for the regulation of metabolic processes and maintenance of normal glucose 
levels.67 Thus, insulin secretion is enhanced in response to increased glucose levels, fatty 
acids and amino acids. In addition, insulin stimulates glucose uptake in the muscle and 
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adipose tissue. Insulin also increases fatty acid synthesis in hepatocytes and adipocytes 
and reduces adipocyte free fatty acid production.67 Usually, insulin signaling involves the 
binding of insulin to its receptor, composed of two substrates (insulin receptor substrates 
1 and 2 (IRS1/2) with two α and two β subunits).68 The binding activates tyrosine kinase 
activity which results in autophosphorylation of the receptors on specific tyrosine 
residues and formation of binding sites for the recruitment of IRS1/2. Subsequent 
phosphorylation of IRS1/2 by the insulin receptor stimulate the phosphatidylinositol 3-
kinase (PI3K)-AKT/protein kinase B (PKB) pathway which regulates metabolic 
functions of insulin including glucose homeostasis and fat regulation.68 Many cell lines 
have shown that the PI3K-AKT/protein kinase B (PKB) activation is essential for the 
translocation of the glucose transporter 4 (GLUT 4) to the plasma membrane for glucose 
uptake in skeletal muscle and adipose tissue.69 Thus, a disturbance of insulin-mediated 
signaling pathway may result in systemic hyperglycemia which is known as insulin 
resistance.  
An imbalance between circulating pro- and anti-inflammatory adipocytokines 
may promote insulin resistance in the liver and muscle. Adipocytokines circulate as 
signaling molecules to communicate not only with adipose tissue itself but also other 
organs such as liver and muscle.36-38 Their interaction with these other insulin sensitive 
organs, in particular the liver have been shown to activate key inflammatory signaling 
pathways such as the cJun N-terminal kinase (JNK) and inhibitor of nuclear factor kappa-
B kinase subunit beta/nuclear factor κB (IKKβ/NF-κB).70-71 IKKβ/NF-κB pathways 
promote the expression of numerous genes involved in inflammatory processes which 
contribute to impaired insulin signaling and induce insulin insensitivity, insulin resistance 
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and increased insulin levels.33,70-72 In addition, serine/threonine (Ser) residues on IRS1/2 
may be phosphorylated instead of tyrosine residues to suppress downstream processes of 
insulin signaling leading to insulin resistance. JNK is a stress kinase that has been shown 
to phosphorylate IRS on Ser-307 residues to promote insulin resistance.70 Because the 
effects of insulin are blunted in insulin resistance as a result of ineffectiveness of insulin 
receptors, pancreatic β cells are persistently stimulated to produce and secrete insulin, and 
this eventually results in the development of T2D.  
Persistent increased fat deposition off-sets a vicious cycle, where the 
adipocyte/macrophage system activates JNK and IKKβ/NF-κB pathways which leads to 
increased secretion of pro-inflammatory adipocytokines and these in turn act directly on 
both adipocyte/macrophage system and JNK and IKKβ/NF-κB pathways.33 Adiponectin 
on the other hand exhibits its anti-diabetic beneficial properties in insulin sensitivity 
through activation of AMP-dependent protein kinase (AMPK) to enhance glucose 
uptake.73 Adiponectin also inhibits production of pro-inflammatory adipocytokines in 
macrophages through suppression of NF-κB activation.74 Besides acting in concert to 
activate the cJun N-terminal kinase (JNK) and inhibitor of nuclear factor κB kinase 
β/nuclear factor κB (IKKβ/NF-κB) inflammatory pathways, pro- and anti-inflammatory 
adipocytokines may act individually through other pathways to affect insulin resistance.  
IL-6 and CRP on Insulin Action:  
IL-6 is a pleiotropic adipocytokine that is reported to regulate the activities of 
several tissues and cells including proliferation of hematopoietic cells, induction of acute 
phase response in the liver and inflammation in tissue injury.75 IL-6 is considered to 
possess both pro- and anti-inflammatory properties.76 Research has associated IL-6 to the 
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modulation of glucose and lipid metabolism through pathways connected to insulin 
action.77-78 IL-6 inhibits insulin receptor signal transduction in hepatic cells by enhancing 
the expression of the suppression of cytokine signaling-3 (SOCS-3) pathway to induce 
insulin resistance.79 However, in a study using animal models, mice that had developed 
hepatic inflammation due to IL-6 deficiency showed improvement in insulin sensitivity 
upon administration of IL-6.80 Moreover, the role of IL-6 in insulin resistance in other 
tissues such as skeletal muscle and adipose tissue is inconsistent.81 In humans, the 
administration of IL-6 to healthy individuals increased fasting blood glucose levels, 
potentially by inducing insulin resistance.82 While IL-6 has been generally considered to 
play a role in insulin resistance, some investigators have suggested that IL-6 prevents 
insulin resistance.83 The discrepancies in reports linking IL-6 to insulin resistance has 
been attributed to the likely dependence on the site, level and duration of IL-6 expression 
and its anti-inflammatory properties.76,80-81 C-reactive protein is induced by IL-6 and is 
synthesized by the liver.20 CRP acts as part of the innate immune system and induces 
phagocytosis of macrophages. In acute inflammation, CRP marks damaged cells to make 
them easier to be recognized by macrophages.84 Several studies have associated insulin 
resistance with increased CRP levels depicting its role in chronic low-grade inflammation 
and metabolic disease processes.85-87 The mechanism through which CRP may induce 
insulin resistance is unclear. However, it is possible that CRP propagates the 
inflammatory and insulin resistance effects of IL-6.  
Leptin on Insulin Action: 
 Leptin is the first adipocytokine to be isolated from the adipose tissue.88 Leptin is 
a product of the human obese (ob) gene located on chromosome 7.89 Human leptin is a 
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16kDa protein of 167 amino acids. It is released into circulatory from the adipose tissue 
and acts in the hypothalamus to control hunger and energy expenditure and thus regulates 
body weight.90 Thus, leptin deficient mice display marked obesity and insulin 
resistance.88 Until decades ago, leptin had been considered to only play a role in 
regulation of energy balance. More recent data shows that leptin is a pro-inflammatory 
adipocytokine and also seems to play a role in inflammatory response. Leptin has 
structural properties similar to IL-6 and is indicated to also induce insulin resistance 
through the SOCS-3 pathway.91 In addition, leptin interacts with the immune system to 
enhance the release of pro-inflammatory IL-6 and TNF-α by macrophages.92-93 This 
integrated system of pro-inflammatory adipocytokines augments the resistant effect of 
leptin on insulin action. It is also suggested that leptin may directly regulate the secretion 
of insulin by pancreatic β cells.94 Leptin levels increase with increasing BMI due to leptin 
resistance and this is attributable to impaired leptin transport in blood brain barrier which 
is induced by SOCS-3.91 
Chemerin and Omentin on Insulin Action: 
In vivo and in vitro studies have demonstrated that chemerin may influence 
glucose homeostasis through reduction of insulin sensitivity.95-96 The effect of chemerin 
on insulin action is suggested to be elicited through alteration of GLUT2 expression 
and/or activity.97-98 GLUT2 promotes insulin secretion in pancreatic β cells by increasing 
the intracellular levels of glucose.98 Evidence supporting the reduction of glucose-
induced insulin secretion was demonstrated in chemerin deficient mice. Chemerin and its 
receptor signaling positively modulated the expression of the pancreatic β-cell-specific 
transcriptional factor, MafA, expressed in pancreatic β cells that positively influence 
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GLUT2 activity.98 Thus, reduction of MafA and subsequently GLUT2 expression may be 
the explanation for the reduced insulin release. Omentin is an anti-inflammatory 
adipocytokine that is inversely associated with obesity and insulin resistance.63 Omentin 
has therefore been shown to enhance insulin sensitivity by increasing the Akt/PkB 
phosphorylation and promoting insulin-facilitated glucose uptake in human omental and 
subcutaneous adipocytes.65 The mechanism by which omentin achieves the positive 
effect on insulin action remains to be clarified. 
The role of insulin resistance in mediating adiposity induced-inflammation and 
the development of MetS and T2D is recognized as an interplay between the metabolic 
and immune pathways.34 Insulin has pleitropic functions and as such, insulin resistance 
and insulin deficiency result in hyperglycemia. The hyperglycemia state is closely linked 
with other metabolic derangement such as hypertension and hyperlipidemia due to further 
activation of inflammatory pathways.99 Taken together, the balance of animal and human 
studies support a role for all these adipocytokines as regulators of insulin resistance, the 
core defect that underlies the development of MetS and T2D. 
Roles of Adipocytokines in Metabolic Syndrome and Type 2 Diabetes  
  Various cross-sectional studies, longitudinal studies and randomized control trials 
conducted to investigate the association between obesity and the effects of 
adipocytokines in the development of insulin resistance and subsequently MetS and T2D 
have shown conflicting results. While some studies demonstrated positive associations, 
others found no significant associations.  
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IL-6 and CRP with MetS and T2D:  
Abbatecola et al.100 used a cross-sectional study design to evaluate the association 
between pro-inflammatory adipocytokines, insulin resistance and components of the 
MetS, which the researchers termed as insulin resistance syndrome. Insulin resistance 
was calculated with the homeostatic model assessment (HOMA-IR). This large 
population-based study conducted in 1146 older persons without T2D, showed a positive 
correlation between plasma levels of TNF-α, IL-6, CRP, interleukin-1 receptor antagonist 
(IL-1ra) and soluble IL-6 receptor (sIL-6R) and insulin resistance. Moreover, as the 
degree of insulin resistance increased, the levels of TNF-α, IL-6, CRP, and IL-1ra also 
increased. In addition, body mass index (BMI), a measure of obesity, triglycerides (TG) 
and IL-6 were associated with higher insulin resistance.  
A study that measured the levels of TNF-α, IL-6, and CRP, and their soluble 
receptors, in obese postmenopausal women with and without MetS showed significantly 
higher levels of soluble TNF-α receptor 1 (sTNFR1) in those with MetS. The number of 
MetS components significantly correlated with plasma concentrations of sTNFR1, but 
was not related to plasma TNFα, sTNFR1, IL-6, IL-6sR, or CRP. The authors concluded 
that the severity of the MetS is associated with body composition, visceral adiposity, and 
inflammation.101  
The Women’s Health Initiative study prospectively investigated the relationships 
of plasma levels of tumor necrosis factor α receptor 2 (TNF-α-R2), IL-6, and CRP with 
the incidence of T2D. The study included non-Hispanic white, Hispanic, non-Hispanic 
Black and Asian/Pacific Islander women aged 50 to 79 years. After a follow-up period of 
5.9 years, 1584 women who developed T2D were matched with 2198 women who did 
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not have T2D. The results of the study showed that all three pro-inflammatory 
adipocytokines were significantly associated with increased T2D risk, however CRP had 
the highest estimated relative risk. Moreover, mutual adjustment for each adipocytokine 
did not attenuate the consistent and significant associations of IL-6 and CRP with 
increased risk of T2D in all ethnic groups. Subgroup analysis indicated more evident 
interactions of TNF-α-R2, IL-6, and CRP with T2D risk in women with BMI ≥25 
kg/m2.12 
Han et al.102 have also considered the role of CRP in the development of both 
MetS and T2D in the same study. The researchers studied 515 men and 729 women who 
were free of diabetes at baseline, but had one or none of other metabolic condition 
including hypertension and dyslipidemia. Serum levels of CRP, indices of adiposity, 
insulin resistance, plasma glucose concentrations, lipid profile and blood pressure were 
measured at baseline and at the end of the study (6 years). CRP correlated significantly 
with components of the MetS in both men and women. Men had a lower risk to develop 
MetS compared to women and this corresponded with lower BMI, waist circumference, 
lower concentrations of CRP, HOMA-IR, high density lipoprotein cholesterol (HDL-C), 
TG, lower levels of systolic blood pressure (SBP) and diastolic blood pressure (DBP) in 
men. Subjects with the highest risk to develop MetS and T2D also had the highest levels 
of CRP at baseline. A comparison of the clinical value of CRP with adiposity and insulin 
resistance measures as a risk factor for the development of MetS showed that the 
combined effects of CRP, BMI and HOMA-IR had greater predictive power than the 
individual markers.  
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Leptin with MetS and T2D: 
There is abundant data indicating that leptin can impact insulin sensitivity and that 
hyperleptinaemia may underlie insulin response. Some evidence also exist which provide 
further insight into possible association between leptin and MetS and T2D. Zimmet et 
al.103 in a population-based study of Western Samoans with and without T2D, determined 
the relationship of serum leptin with insulin sensitivity measured by HOMA and 
components of the MetS. While the results indicated higher leptin levels in men with than 
without T2D, adjustment of BMI made the difference no longer significant. Leptin levels 
did not differ between women with and without T2D. Leptin was significantly, positively 
correlated with BMI, insulin levels, and SBP and DBP when age and gender were taken 
into consideration, irrespective of diabetes status. Moreover, in regression models, leptin 
was associated with insulin sensitivity independent of age, BMI, waist/hip ratio, TG, 
HDL-C, SBP and DBP levels. Furthermore, evidence supporting the relationship of leptin 
with insulin action in T2D was demonstrated by Ozata et al.104 who found that 
improvement in glycemic control following a 4 month treatment with sulfonylurea in a 
group of poorly controlled obese women with T2D matched with those without T2D was 
associated with reduced serum leptin levels. However, this was not associated with 
correction of lipid abnormalities.  
In Mexican Americans, the serum leptin levels were analyzed in relation to 
obesity and T2D. The results of the study indicated that leptin resistance is prevalent in 
this Hispanic ethnic minority subgroup. In addition, higher leptin levels were associated 
with obesity irrespective of diabetes status.105 In 144 Saudi Arabian men, higher leptin 
levels were associated with T2D and coronary heart disease risk factors. Moreover, leptin 
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levels were positively associated with TG and SBP when individuals were obese and had 
insulin resistance and findings were also associated with MetS.106 Conversely, 
Abdelgadir and colleagues.107 found that higher levels of leptin were not associated with 
T2D in 104 indigenous Africans from Sudan with T2D. Despite the finding of no 
association, serum leptin levels positively correlated with HOMA of both beta-cell 
function and insulin resistance in individuals with T2D and only insulin resistance in 
those without T2D.  
Chemerin and Omentin with MetS and T2D: 
There is limited research on the relationship of chemerin and omentin with MetS 
and T2D, but available data have shown positive associations.  
Bozaoglu et al.55 found that in an animal model of obesity and T2D, gene 
expression of chemerin was significantly higher in the adipose tissue of obese and T2D 
models than lean and normoglycemic models. When the investigators measured serum 
levels of chemerin in human samples, there was no significant difference between those 
with compared to without T2D. However, chemerin levels were significantly associated 
with BMI, TG and blood pressure measures in individuals without T2D. In a cohort of 55 
healthy non-obese Caucasians and 181 at risk for the MetS, chemerin was evaluated as a 
marker of MetS and its predictive accuracy was determined. Chemerin levels were higher 
in individuals with the MetS than in healthy controls. Moreover, serum chemerin levels 
positively correlated with age, serum glucose, HDL-C, TG, blood pressure and the 
number of metabolic risk factors. With a cut-off value of 240µg/L, chemerin predicted 
presence of MetS with a 75% sensitivity and 67% specificity.108 
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 Available data have shown that circulating levels of omentin are significantly 
decreased in obese individuals and those with T2D.109 Additionally, circulating omentin 
levels are reduced in association with BMI, leptin, waist circumference (WC), HOMA-IR 
and increased with adiponectin and HDL-C.110 Clinical studies have also revealed a 
positive association between omentin levels and vascular health, suggesting an important 
role for omentin in cardiovascular diseases.63,66 
Pan et al.64 utilized a cohort with impaired glucose tolerance, newly diagnosed 
and untreated T2D individuals and healthy controls. Serum omentin levels were assayed 
and their relationship with BMI, glycated hemoglobin (A1C), plasma glucose, fasting 
insulin, HOMA-IR, TNF-α and IL-6 levels were determined. The results indicated that 
serum omentin levels were lower in those with glucose tolerance and T2D than in the 
control group. There was a negative correlation between omentin levels and BMI, 
HOMA-IR, plasma glucose, fasting insulin, TNF-α and IL-6. Further, HOMA-IR and 
BMI were the independent predictors of serum omentin levels. A similar research 
undertaken by Shibata and colleagues111 using Japanese men without diabetes further 
demonstrated the role of omentin in MetS. The authors investigated the association of 
omentin with the metabolic risk factors. In this study, subjects were categorized 
according to omentin levels as group 1 (those having <2.59 ng/ml); group 2 (those having 
≥2.59 ng/ml); group 3 (those having ≥2.66 ng/ml) and group 4 (those having ≥2.72 
ng/ml). The results of the investigation showed an inverse correlation between omentin 
levels and the number of metabolic risk factors including WC, dyslipidemia, high blood 
pressure and glucose intolerance.  
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Existing studies that examined ethnic differences in established adipocytokines 
such as TNF-α, IL-6 and CRP have focused on general ethnic categories and not 
individual subgroups of ethnicities.12,112-114 Haitian and African Americans are two 
distinct ethnic minority subgroups but are commonly classified as non-Hispanic Blacks. 
As a result, it is unclear whether adipocytokines may differ between Haitian and African 
Americans and whether this difference may distinguish risk for T2D and related health 
outcomes between the two ethnic subgroups. Despite having a better diet quality, Haitian 
Americans have the worse glycemic control compared to African Americans.115-116 Such 
an important difference supports the need to treat each ethnicity as distinct in diabetes 
studies and specifically target ethnic minority subgroups in order to identify and reduce 
disease risks typical for each ethnicity. 
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Specific Aims and Hypotheses 
Specific Aim 1: To evaluate the relationships between metabolic syndrome and 
inflammation, as measured by serum levels of IL-6 and CRP in Haitian and African 
Americans with and without T2D. 
Hypothesis 1: 
a. Metabolic syndrome will be positively associated with IL-6 and CRP levels, 
independent of diabetes status and ethnicity. 
b. Haitian Americans with T2D will have increased levels of IL-6 and CRP, 
compared to African Americans with T2D. 
Rationale: Adipocytokines play important roles in nutrient metabolism and the 
subsequent development of metabolic syndrome. This aim will provide information on 
differences in these adipocytokines between Haitian and African Americans and 
participants with and without T2D and their association with metabolic syndrome. 
Specific Aim 2: To investigate the relationships of two novel adipocytokines: chemerin 
and omentin; diabetes status; and two non-Hispanic Black ethnicities: Haitian and 
African Americans. 
Hypothesis 2: 
a. Type 2 diabetes (T2D) will be positively associated with chemerin levels and 
negatively associated with omentin levels, independent of ethnicity. 
b. Haitian Americans with T2D will have increased chemerin levels and reduced 
omentin levels, compared to African Americans with T2D. 
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Rationale: T2D is considered a state of chronic low-grade inflammation. Haitian 
Americans have been found to have worse glycemic control and T2D outcomes compared 
to African Americans. This aim will therefore enable us understand these novel 
adipocytokines and the differences in these markers not only between participants with 
and without diabetes but between the two ethnicities and further explain those factors 
which are independently linked with inflammation in this population. 
Specific Aim 3: To assess the relationships between BMI, insulin resistance, as measured 
by homeostatic model of assessment-insulin resistance (HOMA-IR) values and leptin in 
Haitian and African Americans with and without T2D. 
Hypothesis 3: 
a. BMI and insulin resistance are positively associated with leptin levels, 
independent of diabetes status and ethnicity. 
b. Haitian Americans with T2D will have increased levels of leptin, compared to 
African Americans with T2D. 
Rationale: Leptin, a pro-inflammatory adipocytokine is increased in obesity and is linked 
to insulin resistance and T2D. This aim will enable us to understand the relationships 
between leptin, obesity and insulin resistance and how they differ by ethnicity and 
diabetes status. 
Research presented here analyzed secondary data from the parent study conducted 
by Huffman et al. (2009) which was to compare cardiovascular risk factors of ethnic 
minorities with and without T2D. In addition, existing serum of participants from the 
parent study stored at -700C was used to obtain data on the serum levels of 
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adipocytokines. While serum levels of IL-6, leptin, chemerin and omentin were measured 
in the Human Nutrition Laboratory at Florida International University, CRP levels were 
obtained from the parent study. TNF-α which was initially proposed to be part of this 
research was not included in the analyses due to its extremely low detectability in more 
than 50% of the samples assayed. For the purposes of this dissertation, discussions will 
be restricted to IL-6, CRP, leptin, chemerin and omentin. The results of the research will 
be discussed as three separate manuscripts which will focus on the specific aims and 
hypotheses described. 
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CHAPTER III:  INFLAMMATORY ADIPOCYTOKINES AND METABOLIC 
SYNDROME IN HAITIAN AND AFRICAN AMERICANS WITH AND WITHOUT 
TYPE 2 DIABETES 
ABSTRACT  
Background: Obesity and metabolic syndrome (MetS) often occur jointly and have been 
associated with type 2 diabetes and cardiovascular diseases. These metabolic processes 
may partially be explained by a pro-inflammatory state. Ethnic subgroups within the non-
Hispanic Black population have not been characterized in metabolic disorder studies. The 
purpose of this study was to assess levels of IL-6 and CRP by ethnicity and diabetes 
status; and determine whether MetS will be associated with higher levels of IL-6 or CRP. 
Methods: Cross-sectional data from 471 participants (230 Haitian Americans and 241 
African Americans; 240 with and 231 without T2D) recruited from various community 
sources in South Florida, were included in this study. Results: African Americans had 
higher log IL-6 and log CRP levels than Haitian Americans (P<0.001). Haitian 
Americans with and without MetS had lower log IL-6 levels and log CRP than African 
Americans with and without MetS, respectively (P < 0.001). Log IL-6 and log CRP 
correlated with higher waist circumference in all groups except for log IL-6 in African 
Americans without T2D. Log IL-6 and log CRP positively correlated with triglycerides in 
Haitian Americans with T2D. Log IL-6 was negatively correlated with HDL-C in Haitian 
Americans with T2D. Higher levels of log CRP (β = 0.34, SE = 0.14, P = 0.012), but not 
log IL-6 (P = 0.727) were associated with MetS. Conclusion: Ethnic-centered health 
interventions that focus on improving these metabolic parameters may be the key to 
reducing the risk for T2D and cardiovascular diseases in this population. 
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INTRODUCTION 
Metabolic syndrome (MetS), the clustering of complex abnormalities, includes a 
large waist circumference, dyslipidemia, hypertension, and impaired glucose tolerance. 
These components of MetS, are a multiplex risk factor for type 2 diabetes (T2D) and 
cardiovascular diseases (CVD).1-3 Population based estimates from the National Health 
and Nutrition Examination Survey (NHANES) 1999-2006 show that approximately 1 out 
of every 3 adults ≥ 20 years has MetS.4 Given the dramatic trend in the increasing 
prevalence of obesity, it is projected that the prevalence of MetS will nearly double in the 
next 15 years.4 The association of MetS with obesity is largely due to chronic low-grade 
inflammation found in both states.5-9 Obesity is associated with dysfunctional adipose 
tissue which leads to altered physiological balance of adipocytokines and is associated 
with hyperinsulinemia, insulin resistance, and a pro-inflammatory state. The recognition 
of the key role of chronic low-grade inflammation in the clinical expression of MetS has 
developed in the past decade.9 Interleukin-6 (IL-6), an important pro-inflammatory 
adipocytokine released by adipocytes has been found to integrate key metabolic pathways 
including insulin signaling, glucose and lipid metabolism.10 IL-6 regulates hepatic acute-
phase response and stimulates the production of C-reactive protein (CRP) by the liver.11 
Recent in vitro studies have demonstrated the extrahepatic production of CRP by human 
adipocytes,12 which elicits the likelihood that CRP may basically be a marker of obesity 
in individuals who later develop MetS and T2D. Several studies have demonstrated an 
increase in circulating levels of IL-6 and CRP in subjects with MetS.13-16 The graded 
positive relationships between IL-6 and CRP, and components of the MetS, particularly 
waist circumference, a measure of obesity, and hyperinsulinemia have also been 
42 
 
reported.13,16 Similarly, high serum IL-6 and CRP have shown significant associations 
with MetS in individuals with and without T2D in diverse racial and ethnic 
populations.13,17-18 
Metabolic syndrome and levels of IL-6 and CRP vary widely across self-
described race/ethnic groups in the United States.4,19 Studies have consistently shown that 
African Americans as compared to Mexican Americans and Whites are less likely to be 
classified as having MetS due to lower prevalence of dyslipidemia.20-22 Yet, African 
Americans exhibit somewhat increased hyperinsulinemia, hypertension, and higher 
prevalence and risk of T2D and cardiovascular diseases.4,23 Moreover, African Americans 
as compared to Whites have higher levels of IL-6 and CRP.24-25 Whereas a sizeable 
number of studies have described the associations between MetS, inflammation and long 
term metabolic disease risks in African Americans, these associations among Haitian 
Americans are lacking, despite their high susceptibility to develop T2D with poor 
outcomes.26 African Americans as compared to Haitian Americans are found to be more 
obese and have increased hyperinsulinemia, two major underlying defects associated with 
MetS.27 Considering the fact that these two components of MetS are also strong 
determinants of IL-6 and CRP levels, the observed differences may have the potential to 
confer variability in the levels of IL-6 and CRP and their association with MetS among 
the two ethnic subgroups. Therefore, this study aimed to analyze Haitian and African 
Americans with and without type 2 diabetes to 1) determine the differences in levels of 
IL-6 and CRP by ethnicity, diabetes and MetS statuses; 2) assess whether MetS will be 
associated with higher levels of IL-6 and CRP. 
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METHODS  
Research design and Participants 
This was a cross-sectional study conducted to study cardiovascular risk factors in 
Haitian and African Americans with and without T2D. Study participants were recruited 
from Miami- Dade and Broward Counties, Florida. African American participants with 
and without T2D were randomly selected from lists of addresses obtained from the 
Knowledge Base Marketing, Inc., Richardson, TX, USA. About 7550 letters were mailed 
to African Americans to request their participation. Of the letters mailed, 4% (n = 256) 
responded. As a result of unavailability of a similar database of mailing addresses for 
Haitian Americans, community based sources were used to recruit Haitian Americans (n 
= 259). Recruitment print advertisements were posted in local Haitian supermarkets, 
churches, and restaurants; and flyers were also distributed to Florida International 
University (FIU) faculty, staff and students. In addition, local diabetes educators and 
community health professionals were requested to assist in recruitment efforts and 
announcements were also aired on a Creole radio station. Interested individuals were 
interviewed on phone and were fully informed of the study purpose. For all those 
interviewed, age, gender and self-identified ethnicity (African American and Haitian 
American) were confirmed. Self-reported T2D status was confirmed based on fasting 
plasma glucose (FPG) and glycosylated hemoglobin (A1C), diabetes duration and use of 
diabetes medications. Eligibility also included age ≥35 years and absence of chronic 
conditions such as kidney failure, hepatitis, HIV and cancer. Eligible respondents were 
requested to participate in the study at the Human Nutrition Laboratory at FIU. 
Participants were directed to be in a fasting state, and refrain from smoking and 
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exercising 8 hours prior to their visit. This study was approved by the Institutional 
Review Board at FIU. Signed informed consent in English or Creole was obtained from 
participants on their initial appointments to the laboratory. Twelve participants (Haitian 
Americans = 8; African Americans = 4) were reclassified as having diabetes according to 
the criteria specified by the American Diabetes Association and referred to their 
physicians. Participants with missing values (n = 34) and outliers (n = 4) for IL-6 were 
excluded. The final data analysis was confined to 230 Haitian Americans and 241 African 
Americans with complete data on IL-6, CRP and MetS.  
Measurement of Study Variables 
a. Socio-demographic 
A validated socio-demographic questionnaire was used to collect information on age, 
gender, smoking status, and use of lipid, nonsteroidal anti-inflammatory drugs (NSAIDs) 
and oral hypoglycemic medications.  
b. Anthropometric measurement 
Height and weight were measured to the nearest 0.5 cm and 0.1 kg respectively, using a 
SECA balance scale (Seca Corp, Columbia, MD). BMI was calculated as weight in 
kg/height in m2. Waist circumference was measured with a non-stretchable measuring 
tape, midway between the lower rib margin and the iliac crest and was reported to the 
nearest 0.1 cm. Blood pressure was measured twice and averaged with the participants in 
a sitting position at rest for fifteen minutes with a sphygmomanometer. 
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c. Blood sampling and biochemical analysis 
Venous blood samples were collected from each participant after an overnight fast of at 
least 8 hours. A trained and certified phlebotomist was in charge of blood draw and this 
ensured minimal risk to the participants. Blood samples were collected in a Vaccutainer 
Serum Separator tube, then coagulated for 30-45 minutes and centrifuged at 2500 RPM 
for half an hour to obtain serum. The serum was aliquoted into 3 labeled plastic tubes for 
1) glucose determination 2) lipid panel analysis and 3) stored at -700C for subsequent 
analyses. Glucose levels were determined by hexokinase enzymatic methods, and lipid 
panel was assayed using enzymatic methods (Laboratory Corporation of America, FL, 
USA). Glycated hemoglobin (A1C) was measured in whole blood samples via Roche 
Tina Quant method (Laboratory Corporation of America, FL, USA). Serum fasting 
insulin levels were determined using a commercially available enzyme-linked 
immunosorbent assay (ELISA, Millipore, St Charles, MS, USA). Serum C-reactive 
protein (CRP) was analyzed with the Immulite method (Vascular Disease Intervention 
and Research Laboratory, OK, USA). Interleukin 6 (IL-6) was measured in serum at the 
Human Nutrition Laboratory at FIU with the ELISA method (BD Biosciences, San Jose, 
CA, USA). Briefly, 50µl of ELISA Diluent was pipetted into each well followed by the 
addition of 100µl of standards, blank and samples. After 2 hours of incubation at room 
temperature followed by washing, 100µl of Working Detector was added and incubated 
for an hour. After a second washing step, 100 µl TMB One-Step Substrate Reagent was 
added and incubated for half an hour. The reaction process was stopped by addition of 50 
µl of Stop Solution. The absorbance of the resulting product was measured at 450nm with 
a spectrophotometer. A microplate reader capable of creating a standard curve plotted the 
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mean absorbance values against the IL-6 concentrations of standards. The software used 
the standard curve to determine the concentrations of the unknown samples. The 
sensitivity of the ELISA assay was 2.2 pg/ml and the range was 2.2–300 pg/ml. The 
intraassay and interassay coefficients of variation were both less than 10%.  
d. Metabolic syndrome (MetS) definition 
The National Cholesterol Education Program Adult Panel III (NCEP-ATP III) criteria for 
MetS1 was used to classify participants as having MetS if they met three or more of the 
following: 1) waist circumference (WC) > 102 cm for men and > 88 cm for women; 2) 
fasting plasma glucose (FPG) ≥ 110 mg/dL; 3) triglyceride (TG) ≥ 150 mg/dL; 4) high-
density lipoprotein cholesterol (HDL-C) < 40 mg/dL for men and < 50 mg/dL for 
women; or 5) systolic blood pressure ≥ 130 mmHg and/or diastolic blood pressure ≥ 85 
mmHg.  
Data Analysis 
The IBM Statistical Package for the Social Sciences (SPSS) version 21 (IBM 
Corporation, Chicago, IL, USA) was used for statistical analyses. Because the 
distributions of insulin, IL-6 and CRP values were skewed, these variables were log-
transformed to approach normality. Descriptive statistics using independent samples t-test 
and analysis of variance (ANOVA) followed by Tukey post hoc tests, for continuous 
variables and χ2 tests for categorical variables were used to assess the differences in 
means stratified by ethnicity, diabetes status and MetS to test the first aim. To evaluate 
the second aim, partial correlations adjusted for age, gender and BMI, and hierarchical 
multiple linear regressions were conducted. The log transformed serum concentrations of 
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IL-6 and CRP served as dependent variables in separate linear regression equations, and 
MetS (yes/no), ethnicity (Haitian Americans/African Americans) and diabetes status 
(yes/no) as independent variables. Regression models were adjusted for age, gender 
(male/female), BMI, smoking (yes/no), NSAIDs (yes/no), lipid and oral hypoglycemic 
medications (yes/no). The results were considered statistically significant at P-value 
<0.05.  
RESULTS 
The demographic and clinical characteristics of the participants are shown as 
comparison of means stratified by ethnicity and diabetes status (Table 1). Overall, both 
Haitian and African Americans had similar prevalence of the MetS and T2D. Haitian 
Americans as compared to African Americans were significantly older (56.3±10.5) and 
had higher A1C and SBP. African Americans had significantly higher mean serum log 
IL-6 (2.14±.5 vs 1.69±.7) and log CRP levels (1.23±1.2 vs 0.50±1.1) than did Haitian 
Americans, respectively (P < 0.001). Compared with Haitian Americans, African 
Americans had higher mean BMI (P< 0.001), WC (P< 0.001), and were more obese (P< 
0.001). African Americans also had higher TG levels (P< 0.001) and log insulin levels 
(P< 0.001), and lower HDL-C (P = 0.017). Current smoking was proportionally higher 
among African Americans (38.2%) than among Haitian Americans (6.5%). African 
Americans were more likely than Haitian Americans to use NSAIDs (39.4% vs 27.4%), 
whereas the use of lipid medications and oral hypoglycemic medications was not 
significantly different between the two ethnic subgroups. The mean age of participants 
with T2D (n = 240) was 55.9±10.2; where the majority were not current smokers (78.7%) 
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and used medications (lipid medications {41.3%}, NSAIDs {42.5%} and oral 
hypoglycemic medications {82.5%}). A significant difference was observed (P<0.05) 
between mean BMI, WC, and percentage obesity of participants with and without T2D. 
Participants with T2D as expected had significantly higher levels of A1C (P< 0.001), 
FPG (P<0.001), SBP (P = 0.024), serum log IL-6 (P = 0.028) and higher percentage of 
MetS (89.6%). The mean log CRP levels (P = 0.239) did not differ significantly between 
participants with and without T2D. Moreover, no significant difference in the levels of 
TG, HDL-C, DBP and log insulin was observed between participants with and without 
T2D.  
Figures 1 & 2 further show the differences in levels of mean log IL-6 and log 
CRP with MetS by ethnicity using ANOVA followed by Tukey post hoc test. Haitian 
Americans with and without MetS had lower mean log IL-6 levels than African 
Americans with and without MetS (1.7±.6 and 1.6±.7 vs. 2.1±.5 and 2.1±.4, respectively; 
P< 0.001). Nevertheless, the mean log IL-6 levels of Haitian Americans with MetS were 
not significantly different from those of Haitian Americans without MetS (1.7±.6 vs. 
1.6±.7; P= 0.123). This observation was also present among African Americans with and 
without MetS (2.1±.5 vs. 2.1±.4; P= 1.000) (Fig. 1). Figure 2 shows that the mean log 
levels of CRP in Haitian Americans with MetS were lower than in African Americans 
with MetS (0.6±1.0 vs. 1.4±1.1; P< 0.001), but not significantly different compared to 
African Americans without MetS (0.6±1.0 vs. 0.7±1.3; P= 0.970). Haitian Americans 
without MetS had lower mean CRP levels compared to Haitian Americans with MetS 
(0.2±1.1 vs. 0.6±1.0; P= 0.017), and African American with and without MetS (0.2±1.1 
vs. 1.4±1.1 and 0.7±1.3; P< 0.001 and P= 0.024, respectively). African Americans with 
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MetS had higher mean log CRP levels compared to African Americans without MetS 
(1.4±1.1 vs. 0.7±1.3; P< 0.001). 
Partial correlations between levels of log IL-6 and log CRP with MetS and each 
component of MetS by ethnicity and diabetes status controlled for age, gender and BMI 
are shown in Table 2. The levels of log IL-6 did not correlate with MetS in neither 
Haitian nor African Americans with and without T2D, whereas log CRP showed a 
positive correlation with MetS among Haitian Americans with T2D and African 
Americans with and without T2D. High levels of log IL-6 and log CRP corresponded 
with higher WC in all groups except for log IL-6 in African Americans without T2D. 
There was a positive correlation between log IL-6 and log CRP with TG only in Haitian 
Americans with T2D (r = 0.35, P< 0.001 and r = 0.18, P= 0.046). In addition, log IL-6 
was negatively correlated with HDL-C in only Haitian Americans with T2D (r = -0.18, P 
= 0.048). Log insulin levels was positively correlated with log CRP in African Americans 
with and without T2D and Haitian Americans without T2D. There was no significant 
correlation between log IL-6 and log CRP with FPG, SBP and DBP in either Haitian or 
African Americans with and without T2D.   
Multiple linear regression models performed to further test the secondary aim that 
MetS will be associated with higher levels of log IL-6 and log CRP are illustrated in 
Tables 3 and 4. The model was run with the primary variables and covariates: age, 
gender, BMI, smoking and intake of NSAIDs, lipid and oral hypoglycemic medications. 
After adjustment, the hypothesis was partially explained since log IL-6 was not 
significantly associated with MetS (Table 3), but MetS explained only log CRP (Table 4). 
Being African American and having a high BMI were positively associated with both log 
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IL-6 and log CRP levels. High levels of log CRP levels were also significantly associated 
with being female, and higher age had a trend towards significant association with higher 
levels of log IL-6 levels. A test of the interaction effect between ethnicity and diabetes 
status showed that the interaction term was not significant. There was no relationship 
between T2D status, current smokers, intakes of NSAIDs, lipid and oral hypoglycemic 
medications with log IL-6 and log CRP.  
DISCUSSION 
The prevalence of metabolic syndrome (MetS), along with type 2 diabetes (T2D) 
and cardiovascular diseases (CVD), has increased steadily in the United States over the 
past decade and is considered as a national epidemic.2-4 MetS and obesity often coexist 
and corresponds to hyperinsulinemia and insulin resistance with increased levels of pro-
inflammatory adipocytokines in persons with MetS.9 African Americans had higher IL-6 
and CRP levels with or without MetS. This may be attributed to the fact that African 
Americans were more obese (higher BMI and WC) and had higher insulin levels. In 
addition, higher IL-6 and CRP levels were seen among participants with than without 
T2D, however, the difference was not significant for CRP. This might be due to only 
modest differences in BMI and insulin levels between the two groups. It is worth 
mentioning that although Haitian Americans had lower metabolic risk factors, their 
prevalence of MetS was similar to that of African Americans. This might be as a result of 
the similar prevalence of T2D among the two groups, since individuals with T2D are 
more likely to have higher prevalence of MetS,28 which is confirmed in our study.  
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Chronic low-grade inflammation, as characterized by increased circulating levels 
of pro-inflammatory adipocytokines, is a key feature of chronic diseases including 
obesity, MetS, T2D and CVD.29 Several studies have associated circulating levels of pro-
inflammatory adipocytokines such as IL-6 and CRP, with metabolic risk factors such as 
obesity and insulin resistance.30 Interleukin 6 is a pleiotropic adipocytokine that plays a 
key role in chronic inflammation.10 It is a central regulator of the acute-phase response 
and a major determinant of hepatic synthesis of CRP.11 IL-6 is secreted by adipocytes and 
macrophages/monocytes recruited into the adipose tissue with increasing adiposity.10 
Thus, IL-6 is considered to not only modulate glucose and lipid metabolism, but the 
innate immunity. IL-6 has been generally considered to play a role in developing insulin 
resistance by inhibiting insulin receptor signaling via expression of suppressor of 
cytokine signaling 3 (SOCS3) in hepatocytes31 and may provide the link between 
metabolic and immune system pathways in the development of MetS and eventually 
T2D. However, some studies have reported that IL-6 is not strongly associated with MetS 
as compared to CRP.32-34 C-reactive protein is the chief downstream mediator of the 
acute-phase response, and may account for the inflammatory and insulin resistance 
effects of IL-6.11,31 Alternatively, reverse causation has been implicated whereby 
decreased insulin sensitivity may enhance hepatic CRP production independent of IL-6 
levels.35 This is because insulin has anti-inflammatory effect which counteracts the 
inflammatory effects of insulin resistance and increased synthesis of hepatic CRP. 
Recently CRP has been produced by adipocytes and may be considered as an 
adipocytokine.12 Among the inflammatory adipocytokines, CRP has been the main focus 
of previous investigations and has been shown to be strongly associated with MetS, T2D 
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and CVD independent of traditional risk factors such as BMI and insulin resistance.12-
13,16,32-34 Moreover compared to other pro-inflammatory adipocytokines, CRP 
measurements are more sensitive due to a relatively long half-life and no circadian 
variation.  
The present study shows a predictable, but partially discordant association 
between MetS and increasing levels of IL-6 and CRP. Specifically, CRP showed a 
significant positive relationship with MetS, whereas a nonsignificant negative 
relationship was observed between MetS and IL-6, after adjusting for BMI and other IL-6 
and CRP confounders. Interestingly, other studies have also shown that CRP, but not IL-6 
is associated with MetS and that CRP seemed appropriate for detecting MetS among 
representative pro-inflammatory markers.32-34 However, the negative relationship in our 
study might be due to the influence of lipid lowering medications taken mainly by 
individuals with MetS to reduce adiposity.36 IL-6 is a direct product of adiposity, a major 
contributor to MetS, thus once adiposity is taken into account, this might have diminished 
association between having MetS and IL-6. On the other hand, CRP is a nonspecific pro-
inflammatory marker which may not be directly affected by adiposity.37 In effect, CRP 
has been shown to be more strongly associated with MetS than IL-6 independent of 
obesity markers and is considered the best standardized pro-inflammatory marker of 
metabolic and cardiovascular disorders.38-40 Pro-inflammatory adipocytokines, 
particularly CRP has therefore been proposed to be considered a component of the 
classification of MetS.41 Moreover, the levels of IL-6 did not correlate with MetS in 
neither Haitian nor African Americans with and without T2D, whereas CRP showed a 
positive correlation with MetS among Haitian Americans with T2D and African 
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Americans with and without T2D. On the other hand, IL-6 correlated with several 
components of the MetS: positively with WC except in African Americans with T2D, TG 
in Haitian Americans with T2D, and negatively correlated with HDL-C in Haitian 
Americans with T2D. This may be in support of the view that chronic inflammation is a 
component of the MetS and may act as the initial trigger to the development of MetS.9,41 
CRP was also positively correlated with WC in Haitian and African Americans with and 
without T2D, TG in Haitian Americans with T2D and log insulin in African Americans 
with and without T2D and Haitian Americans without T2D. Both IL-6 and CRP were not 
correlated with FPG, SBP and DBP in either Haitian or African Americans with and 
without T2D. The lack of correlation of CRP with FPG has been previously reported.32 
Because pancreatic β-cells compensate to increase insulin synthesis earlier on in impaired 
glucose tolerance, FPG levels may remain within normal limits.  
 We found ethnically-specific differences in IL-6 and CRP even when adjusting 
for BMI. One possible reason for the ethnic differences in the level of IL-6 is due to the 
presence of variants of cytokine gene single nucleotide polymorphisms. Delaney et al.42 
discovered that allelic variation in the enhancer regions of the cytokine genes may 
modify the expression of some cytokines. The G/G genotype which causes high 
expression of IL-6 and as a result increases IL-6 production, has been predominantly 
found in African Americans, and may explain higher levels of IL-6 among this ethnic 
subgroup. Additionally, several studies have reported that the association between CRP 
and adiposity does not fully explain the higher CRP levels in populations of African 
ancestry.43-44 In a recent large genome-wide association study, Reiner and colleagues45 
identified several CRP-associated alleles of triggering receptors expressed by myeloid 
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cells 2 (TREM2) in African American women. The authors reported that the strongest of 
these alleles which is associated with higher levels of CRP is present only in African 
ancestral populations. Therefore, future studies should investigate the activities of these 
genes also in Haitian Americans to better distinguish inflammatory processes between the 
two non-Hispanic Black subgroups. Other nongenetic factors such as diet quality and 
lifestyle factors (including physical activity and smoking) which have been shown to be 
better in Haitian Americans than Africans Americans,46 may have accounted for the 
lower inflammatory status in Haitian Americans. Although, smoking was not 
significantly associated with levels of IL-6 and CRP in regression analysis, African 
Americans had a higher percentage of smokers in our study. Smoking has been found to 
be a strong risk factor for the chronic low-grade inflammation based on increased 
circulating levels of IL-6 and CRP.47-48 
The association of inflammatory adipocytokines with diabetes are mixed.49-51 The 
nonsignificant association between IL-6 or CRP and T2D in our study was not expected.  
This could be due to the almost similar levels of BMI and insulin among participants with 
and without T2D. As such, the metabolic alterations and related changes in inflammation 
in participants with T2D was not severe enough to make a significant difference between 
the two groups and difficult to detect. Krakoff et al.50 and Efstratiadis et al.51 investigated 
the association between diabetes and IL-6 or CRP levels and reported no significant 
association between these parameters after controlling for markers of obesity and other 
IL-6 and CRP confounders. However, a meta-analysis of ten studies, involving 19,709 
participants have shown an association between diabetes and higher levels of IL-6 and 
CRP.52 These studies included either only women or only men or both and were 
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conducted either within the US or outside the US. There is the need to further explore 
these findings to better understand the differing results. Despite the lack of association 
with T2D, IL-6 and CRP were strongly associated with known causal risk factors for 
diabetes such as BMI, WC and insulin levels. Thus, the positive relationship between 
chronic low-grade inflammation with adiposity measured by BMI and WC, and insulin 
was observed in our study.  
The results further provide evidence of an association between gender and CRP, 
in congruence with previous investigations that have found higher CRP levels among 
females.53 While our study participants did not differ significantly by gender for ethnicity 
or diabetes status, African Americas and participants with T2D had higher percentages of 
females. Females have always had higher levels of CRP than men,53 a finding that is 
linked to higher BMI and WC, which was present in African Americans and participants 
with T2D in our study. Our findings also revealed that age had a slight tendency of 
significant association with IL-6 levels. IL-6 levels increase with age, apparently 
reflecting the higher inflammation levels as age advances.47 While Haitian Americans 
were older in our study, they had lower levels of IL-6 as compared to African Americans, 
suggesting that this observation may be due to other factors more significant than age in 
this population. 
 Strengths of our study include utilizing a gender-balanced, sample of two 
subgroups of non-Hispanic Blacks; that are not usually compared in most studies. There 
are limited studies to date on ethnic variations for MetS, T2D status and the inflammatory 
burden in nonwhite populations at risk for diabetes and cardiovascular diseases. This is 
the first study to the best of our knowledge that has specifically looked at MetS and its 
56 
 
components, and assessed ethnic differences in the pro-inflammatory adipocytokines, IL-
6 and CRP within this non-Hispanic Black ethnicity with and without T2D. Our findings 
indicate significant differences in MetS components, obesity measures, and serum IL-6 
and CRP levels among Haitian Americans and African Americans, thus, distinguishing 
the two non-Hispanic Black groups and yields important information particularly for 
Haitian Americans, a previously understudied ethnic minority subgroup.  
 The cross-sectional design of this is study is a limitation. As a result, causality 
between ethnicity, obesity measures, MetS, T2D and the levels of pro-inflammatory 
adipocytokines cannot be considered. In addition, the study population is a semi-
convenience sample and not recruited by randomized selection. The sample may 
therefore not be representative of Haitian Americans and African Americans living in 
South Florida and as such, generalizability to the larger population may be limited. The 
IL-6 concentration of 47 of the study participants was undetectable which might be that 
these participants were less predisposed to increased inflammation. Since IL-6 has a short 
half-life (~ 6 hours) and can be difficult to detect among particular populations using 
ELISA kits, future assessment of inflammation should use IL-6 receptor as a surrogate 
for IL-6 levels.  
CONCLUSION 
In summary, this study has important clinical and public health implications. 
Inflammatory based risk for metabolic conditions may vary according to ethnicity and 
other demographic variables in subgroups of non-Hispanic Blacks. The study indicates 
that African Americans with MetS have higher levels of IL-6 and CRP which might be 
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explained by obesity with greater BMI and WC, and hyperinsulinemia. Ethnic-centered 
health interventions that focus on improving these metabolic parameters may therefore be 
the key to reducing the risk for T2D and cardiovascular diseases in this population. 
Future studies to determine genetic variants of the pro-inflammatory markers, and dietary 
and lifestyle factors of Haitian Americans and African Americans alongside their 
association with MetS may be beneficial. 
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TABLE 1. Characteristics of the Participants by Ethnicity and Diabetes Status 
     Ethnicity                                                            Diabetes status 
Variables     Haitian  
  American 
   (n = 230) 
    African 
  American 
   (n = 241) 
 
 P-value 
           With 
            T2D 
         (n = 231) 
      Without  
          T2D 
      (n = 240 ) 
 
P value 
Age (years)   56.3±10.5 52.5±9.5 <0.001         55.9±10.2   52.6±9.8 <0.001 
Female (Yes) n %  120 (52.2) 125 (51.9)  0.947         130 (54.2)   115 (49.8)   0.341 
Diabetes status (Yes) n %                        120 (52.2)                 120 (49.8)          0.605                       -                          -                       - 
Ethnicity  
             HA (Yes) n % 
             AA (Yes) n % 
Smoke (Yes) n % 
 
       - 
       - 
  15 (6.5) 
 
- 
- 
92 (38.2) 
 
     - 
     - 
<0.001 
      
        120 (50.0)    
        120 (50.0)    
        51 (21.3) 
 
 110 (47.6) 
 121 (52.4) 
 56 (24.4) 
 0.605 
- 
- 
0.438 
Lipid meds (Yes) n %   54 (23.5) 70 (29.0)  0.170         99 (41.3)            25 (10.8) <0.001 
NSAIDs (Yes) n %   63 (27.4) 95 (39.4) 0.006        102 (42.5)  56 (24.2) <0.001 
Oral hypoglycemic meds (Yes) n %  106 (46.1) 92 (38.2) 0.082        198 (82.5)             - - 
A1C (%)    7.3±2.3      6.8±1.7 0.004       8.0±2.4 6.0±.7 <0.001 
BMI (kg/m2)   29.4±5.3     33.7±7.9 <0.001       32.7±7.7 30.4±6.1 <0.001 
Obese (BMI ≥30 kg/m2) n %  101 (43.9) 157 (65.1) <0.001        148 (61.7) 110(47.6)    0.002 
WC (cm)  98.5±12.5 108.4±17.6 <0.001       107.3±16.9 99.6±14.2 <0.001 
FPG (mmol/L) 130.4±60.7 122.0±54.9   0.114       151.8±69.7 99.5±20.1 <0.001 
TG (mg/dL) 106.7±56.0   128.2±72.7 <0.001      114.3±64.5 121.1±67.2  0.269 
HDL-C(mg/dL)  53.1±14.5    49.9±13.7  0.017      51.8±14.7      51.2±13.7  0.660 
SBP (mm Hg) 146.2±24.5  1 36.9±19.5 <0.001      139.0±22.6 143.7±22.1 0.024 
DBP (mm Hg)  90.5±13.0    89.0±12.1  0.221       89.8±12.0 89.6±13.1  0.797 
MetS (Yes) n % 160 (69.6)   176 (73.0)  0.406       215 (89.6)      121 (52.4) <0.001 
log Insulin (µIU/mL)     2.0±.7      2.4±.8 <0.001     2.3±.6 2.1±.9 0.059 
log IL-6 (pg/mL)    1.69±.7     2.14±.5 <0.001     1.85±.7 1.99±.6 0.028 
log CRP (mg/L)  0.50± 1.1   1.23± 1.2 <0.001      0.80±1.3 0.94±1.2 0.239 
Data were expressed as mean ± SD unless otherwise indicated. Abbreviations: T2D = type 2 diabetes; NSAIDs = non-steroidal anti-
inflammatory drugs; BMI = body mass index; A1C = hemoglobin A1C; WC = waist circumference; FPG = fasting plasma glucose; TG 
= triglycerides; HDL-C = high density lipoprotein cholesterol; SBP = systolic blood pressure; DBP = diastolic blood pressure; MetS = 
metabolic syndrome; IL-6 = Interleukin 6; CRP = C-reactive protein. P-value is considered significant at <0.05. 
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                    Fig 1. Comparison of levels of log IL-6 by metabolic syndrome and ethnicity 
                              Data were expressed as mean ± SD. Groups with same superscript are not  
                              significantly different assessed by ANOVA, Tukey post hoc, P<0.05.  
                              Abbreviations: HA = Haitian Americans; AA = African Americans;  
                              IL-6 = Interleukin-6; MetS = metabolic syndrome. 
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                   Fig 2. Comparison of levels of log CRP by metabolic syndrome and ethnicity 
                             Data were expressed as mean ± SD. Groups with same superscript are not  
                             significantly different assessed by ANOVA, Tukey post hoc, P<0.05.  
                             Abbreviations: HA = Haitian Americans; AA = African Americans;  
                              CRP = C-reactive protein; MetS = metabolic syndrome. 
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TABLE 2.  Partial Correlations of log IL-6 and log CRP with MetS and Components of MetS by Ethnicity and Diabetes   
                    Status 
                     log IL-6 (pg/mL)  
                          r (p-value) 
                                                        log CRP (mg/L)  
                                                            r (p-value)  
Variables                      HA                  AA                   HA                    AA                           HA                   AA                      HA                    AA 
                                         with T2D         with T2D     without T2D    without T2D              with T2D          with T2D        without T2D    without T2D
 
MetS                        0.14(0.122)       0.04(0.663)      0.03(0.758)      -0.05(0.611)            0.30(<0.001)       0.27(0.003)        0.13(0.189)        0.23(0.011) 
 
WC (cm)                  0.20(0.031)       0.26(0.004)       0.22(0.023)       0.09(0.354)           0.40(<0.001)      0.41(<0.001)      0.23(0.014)       0.39(<0.001) 
FPG (mmol/L)         0.09(0.292)      -0.14(0.142)       0.09(0.314)       0.04(0.660)           -0.01(0.941)        0.04(0.672)       0.13(0.189)        0.14(0.118) 
TG (mg/dL)             0.35(<0.001)     0.02(0.813)       0.09(0.366)      -0.07(0.467)            0.18(0.046)        0.05(0.623)        0.03(0.774)       0.08(0.375) 
HDL-C (mg/dL)      -0.18(0.048)     -0.14(0.135)      -0.02(0.868)      -0.04(0.683)          -0.08(0.365)      -0.11(0.227)        0.05(0.574)       -0.12(0.177) 
SBP(mm Hg)           -0.09(0.308)     -0.04(0.675)     -0.002(0.984)     -0.11(0.235)          -0.11(0.221)      -0.09(0.316)        -0.11(0.243)       0.03(0.711) 
DBP (mm Hg)         -0.06(0.498)     -0.05(0.571)      -0.03(0.727)       0.05(0.621)            0.01(0.940)       0.06(0.535)        -0.07(0.456)        0.10(0.277) 
log insulin(µIU/mL) 0.10(0.271)      0.02(0.868)        0.09(0.367)      0.07(0.464)            0.05(0.560)       0.19(0.036)        0.35(<0.001)      0.33(<0.001)
Data adjusted for covariates; age, gender and BMI. Abbreviations: HA = Haitian American; AA = African American; T2D = type 2 diabetes; MetS = metaboli
syndrome; WC = waist circumference; FPG = fasting plasma glucose; TG = triglycerides; HDL-C = high density lipoprotein cholesterol; SBP = systolic blood
DBP = diastolic blood pressure; IL-6 = inteleukin-6; CRP = C-reactive protein; r = correlation coefficient; P-value <0.05 (2-tail) considered significant.  
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     TABLE 3. Multiple Linear Regression with log IL-6 as Dependent Variable 
 
         Variables 
  
β                        SE                   P-value                            CI% 
                                                                                Lower         Upper 
                                                                                bound         bound 
          Ethnicity                               0.37                    0.07                 <0.001                     0.24             0.50 
          T2D status                            0.07                    0.10                    0.518                   -0.14             0.27 
          MetS                                  -0.03                   0.07 0.727  -0.17   0.12 
Model Summary: F (1,460) = 0.122, P = 0.727; adj R2 = 0.137; Covariates: Age (P = 0.054); Gender (P = 0.592); BMI (P = 0.001); 
Smoke (P = 0.208); NSAIDs (P = 0.816); Diabetes medications (P = 0.643); Lipid medications (P = 0.662); Abbreviations: IL-6 = 
Interleukin 6; β = B coefficient; SE = standard error; T2D = type 2 diabetes; MetS = metabolic syndrome. 
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      TABLE 4. Multiple Linear Regression with log CRP as Dependent Variable 
 
              Variables 
 
β 
                      
                   SE                    P-value                            CI% 
                                                                         Lower          Upper 
                                                                         bound          bound 
               Ethnicity                                0.47                    0.12                  <0.001                    0.24              0.71 
               T2D status                             0.09                    0.19                    0.651                    -0.29             0.46 
              MetS                                     0.34 0.14    0.012      0.07          0.60 
Model Summary: F (1,460) = 6.332, P = 0.012; adj R2 = 0.227; Covariates: Age (P = 0.559); Gender (P = 0.001); BMI (P<0.001); Smoke 
(P = 0.862); NSAIDs (P = 0.360); Diabetes medications (P = 0.237); Lipid medications (P = 0.596). Abbreviations: CRP = C-reactive 
protein; β = B coefficient; SE = standard error; T2D = type 2 diabetes; MetS = metabolic syndrome. 
 70 
 
CHAPTER IV: SERUM CHEMERIN AND OMENTIN IN HAITIAN AND 
AFRICAN AMERICANS WITH AND WITHOUT TYPE 2 DIABETES 
ABSTRACT 
Background: Recently, chemerin and omentin have been identified as novel 
adipocytokines that are associated with obesity, insulin action and the development of 
type 2 diabetes (T2D). The circulating levels of chemerin and omentin and their 
association with T2D among non-Hispanic Black ethnic subgroups have not been studied. 
This study was conducted to determine whether the levels of chemerin and omentin are 
altered by ethnicity and diabetes status. Methods: The study included 429 participants, 
225 without T2D and 204 with T2D (214 Haitian Americans and 215 African 
Americans). African Americans were recruited through mailing lists and Haitian 
Americans through multiple community sources. After informed consent, information on 
socio-demographic variables and clinical data were obtained. Serum levels of chemerin 
and omentin were measured by ELISA and the homeostasis model assessment version 2 
was used to estimate insulin sensitivity (HOMA2-IS).  
Results: Haitian Americans with T2D had significantly lower serum chemerin levels (P 
<0.001) and significantly higher serum omentin levels (P = 0.023) compared to African 
Americans with T2D. Diabetes status was negatively associated with chemerin (B = -
41.35, SE = 18.28, P = 0.024), but not significantly associated with omentin (B = -85.02, 
SE = 56.86, P = 0.136) in the separate models, after adjusting for covariates. HOMA2-IS 
was inversely associated with chemerin (B = -0.229, SE = 0.11, P = 0.030), but not with 
omentin (B = 0.11, SE = 0.33, P = 0.745). Conclusion:  Haitian Americans with T2D had 
lower chemerin and higher omentin levels compared to African Americans with T2D. 
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The lower percentage of obesity in Haitian Americans may explain the lower chemerin 
and higher omentin. The unexpected inverse association of chemerin with diabetes status 
may have been due to the residual confounding effects of medications used mainly by 
participants with T2D. The relationship between chemerin and omentin in T2D should be 
further investigated in prospective studies and drug-naïve individuals. 
INTRODUCTION 
Type 2 diabetes (T2D) is a heterogeneous metabolic disorder characterized by 
impaired insulin sensitivity and/or action and a resulting chronic hyperglycemia.1-3 
Worldwide, T2D has become a public health concern. In the United States (US) alone, 
about 29 million are diagnosed with the disease, accounting for 245 billion dollars in 
annual healthcare costs.4-5 Moreover, important ethnic disparities in T2D prevalence and 
outcomes have been reported.6-7 While the rate of T2D has increased across all ethnic 
groups, non-Hispanic Blacks have had almost a doubling of prevalence of diagnosed 
diabetes since 1988.8 According to the 2014 National Diabetes Statistics Report, the 
prevalence of T2D was 13.2% among non-Hispanic Blacks in 2012; 1.1 times and 1.7 
times higher than in Hispanics and non-Hispanic Whites, respectively.4 Thus, nowadays 
the focus on the effort to reduce the prevalence of T2D should be to conduct studies with 
respect to ethnic differences, particularly within the non-Hispanic Black population.9-10 It 
is suggested that a higher susceptibility to inflammation may account for the increased 
prevalence of T2D among non-Hispanic Blacks.11-12 
Type 2 diabetes is considered a state of chronic low-grade inflammation, and that 
inflammation is suggested to initiate and contribute to the progression of T2D.12-14 It is 
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well recognized that obesity and insulin resistance are prominent factors associated with 
the chronic low-grade inflammation and ultimately the development of T2D.12-15 The 
altered secretion of adipose-derived peptides (adipocytokines)  have considerable 
influence on glucose metabolism in the main target tissues (adipose tissue, muscle and 
liver) of insulin.15-18 Chemerin is a recently discovered pro-inflammatory adipocytokine 
that have been shown to inhibit insulin signaling through the activation of key 
inflammatory modulators such as the nuclear factor-kB signaling pathways.15-19 The 
consequences of these processes are perpetuation of inflammation and decreased insulin 
sensitivity. Chemerin is secreted as an inactive prochemerin and cleaved through serine 
protease activity to the active chemerin.20 Chemerin levels are increased in obese 
individuals and states of impaired insulin sensitivity, insulin resistance and metabolic 
syndrome.20-21 Thus, the role of chemerin in these processes, may explain the relationship 
between obesity, insulin action and T2D. Another candidate, omentin, a newly identified 
adipocytokine is involved in glucose and lipid metabolism.22-23 Omentin is a novel 
adipocytokine with insulin-sensitizing effects similar to adiponectin.23 Obesity, decreases 
visceral adipose tissue expression of the anti-inflammatory adipocytokine omentin.24 In 
several studies, omentin was shown to be significantly decreased in obese individuals and 
those with T2D.24-25  
Previous studies on adipocytokines and obesity-related disorders have been 
focused on TNF-α, leptin, resistin and adiponectin.26-27 Moreover, studies involving 
chemerin and omentin have been conducted mostly among non-Hispanic Whites and 
other Hispanic ethnic subgroups.20,28-29 To our knowledge, to date no studies have 
assessed the novel adipocytokines, chemerin and omentin among non-Hispanic Black 
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subgroups. Considering the burden of disease among non-Hispanic Blacks with regards 
to T2D, it is worth understanding the levels of chemerin and omentin and identify other 
factors associated with T2D in this population. The purpose of this study was to 
determine whether the levels of chemerin and omentin differ by ethnicity and diabetes 
status and we also investigated the relationship of diabetes status with chemerin and 
omentin.  
STUDY SUBJECTS AND DESIGN 
This study was an ancillary study which generated data on adipocytokines from 
stored blood samples of the parent study that compared cardiovascular risk factors in 
non-Hispanic Blacks with and without T2D. The objective of this cross-sectional study 
was to determine the levels of chemerin and omentin in Haitian Americans and African 
Americans with and without T2D and to investigate their relationship to diabetes status. 
Between the period of 2008-2010, study subjects were recruited in South Florida, from 
the Miami- Dade and Broward Counties. African American participants were recruited 
randomly from two mailing lists provided by Knowledge Base Marketing, Inc., 
Richardson, TX, USA. The company generated the list of addresses from several 
databases of African Americans with and without T2D. Approximately 7550 letters were 
mailed to African Americans to request their participation. From the letters that were 
delivered, 4% (n = 256) of the participants responded. Recruitment of Haitian Americans 
(n = 259) was from multiple community based sources since a similar database of mailing 
addresses was unavailable for this group. The recruitment strategies included: i) 
placement of print advertisements in local Haitian supermarkets, churches, and 
restaurants ii) distribution of flyers to Florida International University (FIU) community 
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iii) request to local diabetes educators and community health professionals and iv) airing 
of announcements on Creole radio stations. Telephone interviews were conducted for 
respondents who expressed interest in the study. During the phone calls, the purpose of 
the study was fully explained and final eligibility was assessed (i.e., age – ≥35 years, 
gender and self-identified ethnicity – African American and Haitian American). 
Additionally, T2D status was ascertained based on fasting plasma glucose and 
hemoglobin A1C, diabetes duration and initial treatment modalities. Respondents with 
the following conditions were excluded: kidney failure, hepatitis, HIV and cancer. The 
study protocol obtained ethical approval from the Institutional Review Board (IRB) at 
FIU. Eligible respondents were invited for an enrollment visit at the Human Nutrition 
Laboratory at FIU. Participants were instructed to complete an overnight fast (at least 8 
hours) prior to blood collection, during which they could drink only water, refrain from 
smoking and any unusual exercise. Informed consent in English or Creole with IRB 
ethical clearance was obtained from participants after they understood and agreed to the 
terms on the form. Eight Haitian Americans and 4 African Americans who self-reported 
as having no T2D, yet whose laboratory results showed high values of fasting plasma 
glucose (FPG) and glycated hemoglobin (A1C) for diabetes were reclassified as having 
diabetes and referred to their physicians. Participants (n = 87) with missing values and 
outliers for chemerin, omentin and HOMA2-IS were excluded. Data was available for 
429 participants, 225 without T2D and 204 with T2D (214 Haitian and 215 African 
Americans) for final statistical analysis.  
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METHODS 
Study participants responded to a validated self-reported questionnaire. Trained 
interviewers administered in depth standardized questionnaires to participants to 
complete. Socio-demographic information comprised questions related to age, gender, 
smoking status, and medications used. Height and weight were measured using a SECA 
balance scale (Seca Corp, Columbia, MD). Body mass index (BMI) was calculated as 
weight in kg divided by height in m2.  
Clinical and laboratory assessments 
Following an 8-hour overnight fast, twenty milliliters of venous blood was 
collected in a Vaccutainer Serum Separator tube by a trained and certified phlebotomist 
using standard methods. Blood samples were centrifuged at 2500 RPM for half an hour 
after coagulation. The separated serum was aliquoted into 3 labeled plastic tubes. Two 
were designated for glucose determination and lipid panel analysis. The third aliquot was 
stored at -700C for subsequent analyses. Glucose levels were measured by hexokinase 
enzymatic methods (Laboratory Corporation of America, FL, USA). Hemoglobin A1C 
percentages were assayed in whole blood samples applying the Roche Tina Quant 
method (Laboratory Corporation of America, FL, USA). Fasting serum insulin levels 
were determined with enzyme-linked immunosorbent assay (ELISA) using commercially 
available kits (Millipore, St Charles, MS, USA).  
Chemerin levels in serum were measured at the Human Nutrition Laboratory at 
FIU with ELISA using microtitration plates pre-coated with polyclonal anti-human 
chemerin antibody according to manufacturer’s protocol (BioVendor LLC, Candler, NC, 
USA). Briefly, 100µl of standards, quality controls, dilution buffer (blank) and diluted 
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samples (100x – 5µl sample plus 495µl dilution buffer) were pipetted in duplicates into 
wells on the microplate. After an hour of incubation at room temperature (shaking at 300 
RPM) followed by washing, 100 µl biotin labelled antibody solution was added and 
incubated with the bound chemerin for another hour. After a second washing step, 100 µl 
streptavidin-HRP conjugate was added and incubated for half an hour at room 
temperature (shaking at 300 RPM). The last washing step was performed and the residual 
conjugate was allowed to react with the 100 µl of substrate solution 
(tetramethylbenzidine). The reaction process was stopped by addition of 100 µl of an 
acidic stop solution. The absorbance of the resulting product was measured at 450nm 
with a spectrophotometer. A microplate reader capable of creating a standard curve 
plotted the mean absorbance values against the chemerin concentrations of standards. The 
software used the standard curve to determine the concentrations of the unknown diluted 
samples multiplied by the dilution factor to obtain the actual amount of serum chemerin. 
The sensitivity of the ELISA assay was 0.1 ng/ml and the range was 0.1–8 ng/ml (10–800 
ng/ml with dilution factor). The intraassay and interassay coefficients of variation were 
both less than 10%.  
Serum omentin levels were determined in the Human Nutrition Laboratory at FIU 
using human omentin-1 detection kit (ELISA, BioVendor LLC, Candler, NC, USA) 
according to manufacturer’s protocol. Serum samples were diluted and assayed using 
microplates pre-coated with polyclonal anti-human omentin-1 antibody. Briefly, 100µl of 
standards, quality controls, dilution buffer (blank) and diluted samples (40x – 6µl sample 
plus 234µl dilution buffer, or 60x further dilution for samples that exceeded 2560 ng/ml) 
were pipetted in duplicates into wells on the microplate. After 2 hours of incubation at 
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370C followed by washing, 100 µl biotin labelled antibody solution was added and 
incubated with the bound omentin for half an hour. After a second washing step, 100 µl 
streptavidin-HRP conjugate was added and incubated at 370C for half an hour at room 
temperature. The last washing step was performed and the residual conjugate was 
allowed to react with the 100 µl of substrate solution (tetramethylbenzidine). The reaction 
process was stopped by addition of 100 µl of an acidic stop solution. The absorbance of 
the resulting product was measured at 450nm with a spectrophotometer. A microplate 
reader capable of creating a standard curve plotted the mean absorbance values against 
the omentin concentrations of standards. The software used the standard curve to 
determine the concentrations of the unknown diluted samples multiplied by the dilution 
factor to obtain the actual amount of serum omentin. The intraassay and interassay 
coefficients of variation were both less than 10%. The sensitivity of the ELISA assay was 
0.5 ng/ml and the range was 0.5–64 ng/ml (80–2560 ng/ml with dilution factor). 
Calculation of insulin sensitivity (HOMA2-IS) 
The Oxford University HOMA2 calculator was used to calculate insulin 
sensitivity index as previously described.30 The model determines insulin sensitivity 
index (HOMA2-IS) from paired fasting plasma glucose and radioimmunoassay insulin 
across a range of 1-2,200 pmol/l for insulin, and 1-25 mmol/l for glucose.  
Data Analysis 
Statistical analyses were conducted with SPSS version 21 (IBM Corporation, 
Chicago, IL, USA). The Kolmogorov-Smirnov test was used to assess the normality of 
the distribution of the data. A Student’s t-test was used for continuous variables and χ2 
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tests for categorical variables to compare participants by ethnicity and diabetes status. 
The analysis of variance (ANOVA) was used to compare serum levels of chemerin and 
omentin according to BMI categories (normal weight: BMI<25kg/m2, overweight: BMI 
25kg/m2 - < 30kg/m2 and obese: BMI ≥30kg/m2), followed by Tukey’s post hoc tests. 
The relationships between variables were analyzed by multiple linear regression 
controlling for the covariates including age, gender, BMI, ethnicity (Haitian 
Americans/African Americans), smoke (yes/no), lipid lowering drugs (yes/no), non-
steroidal anti-inflammatory drugs {NSAIDs} (yes/no), oral hypoglycemic medications 
(yes/no) and HOMA2-IS. The serum concentrations of chemerin and omentin were used 
as dependent variables in separate models. A P-value of <0.05 was considered to be 
statistically significant. 
RESULTS 
Tables 1 and 2 show for the characteristics of the participants included in this 
study according to diabetes status and diabetes status by ethnicity.  
The mean age of participants with T2D was 56.0±10.2 years and those without T2D was 
52.1±9.7 years (Table 1). The percentages for the three BMI categories were significantly 
different between participants with T2D as compared to participants without T2D. The 
use of medications (lipid lowering drugs and NSAIDs) in participants with T2D were 
highly significant than in participants without T2D (P<0.001). Fasting plasma glucose 
and A1C in participants with T2D were significantly higher (P<0.001) than in 
participants without T2D. Moreover, fasting insulin levels and HOMA2-IS were not 
significantly different between participants with and without T2D. Serum chemerin and 
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omentin levels were not significantly different in participants with T2D as compared to 
participants without T2D. There was no significant difference by gender between 
participants with T2D as compared to participants without T2D. The percentage of 
smokers in participants with T2D was comparable to that of participants without T2D.   
Table 2 shows that in the group with diabetes, Haitian Americans with T2D were 
significantly older (P=0.009), had lower BMI (P<0.001), lower percentage of smokers 
(P<0.001), higher intake of oral hypoglycemic medications (P=0.002), higher A1C 
(P<0.009), higher HOMA2-IS (P<0.001), lower chemerin levels (P<0.001) and higher 
omentin levels (P=0.023) than did African Americans with T2D. There were significant 
differences also in age, BMI, FPG, A1C, insulin levels, HOMA2-IS and medication use 
by diabetes status and ethnicity. African Americans without T2D were significantly 
younger (P=0.013), had higher insulin levels (P=0.006) and higher percentage of 
smokers (P<0.001). Haitian Americans without T2D had significantly higher mean FPG 
(105.1±29.0) and A1C (6.2±0.9). Serum chemerin levels were significantly lower in 
Haitian Americans without T2D (P<0.001), whereas omentin levels were slightly higher 
in African Americans without T2D, however not significantly. There was no significant 
differences in BMI and HOMA2-IS between Haitian and African Americans without 
T2D. Moreover, African Americans without T2D had higher, but not significantly intake 
of lipid medications and NSAIDs compared to Haitian Americans without T2D.  
We further used ANOVA to analyze the difference in means of serum chemerin 
and omentin levels among participants with and without T2D by BMI categories; the data 
was classified as normal weight: BMI<25kg/m2, overweight: BMI 25kg/m2 - <30kg/m2 
and obese: BMI ≥30kg/m2 (Table 3). Among participants with T2D, those with normal 
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weight had significantly lower chemerin and higher omentin levels compared with those 
who were obese. There was no significant difference in chemerin and omentin levels 
between normal and overweight and overweight and obese individuals. Among 
participants without T2D, there was no significant difference in mean serum chemerin 
and omentin levels with BMI categories. 
Tables 4 and 5 show the multiple linear regressions run with chemerin and 
omentin as dependent variables in separate models. Diabetes status was negatively 
associated with chemerin (B = -41.35, SE = 18.28, P = 0.024), but not associated with 
omentin levels (B = -85.02, SE = 56.86, P = 0.136). African American (B = 38.48, SE = 
11.59, P = 0.001), having a lower HOMA2-IS (B = -0.23, SE = 0.11, P = 0.030), being 
older (B = 1.37, SE = 0.51, P = 0.008) and being female (B = -21.14, SE = 10.15, P = 
0.038) were associated with chemerin. Omentin levels were negatively associated with 
BMI (B = -6.64, SE = 2.66, P = 0.013) and positively associated with age (B = 6.69, SE = 
1.59, P <0.001). A test of the interaction effect between ethnicity and diabetes status 
showed that the interaction term was not significant. 
DISCUSSION 
To date, no studies have characterized the novel adipocytokines, chemerin and 
omentin, among non-Hispanic Black subgroups, a high-risk population for the 
development of type 2 diabetes (T2D). Thus, in this study, we determined the levels of 
serum chemerin and omentin in Haitian Americans and African Americans with and 
without T2D and assessed their relationship with T2D, controlling for important 
covariates. The results of the present study surprisingly revealed a significant negative 
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association between diabetes status and chemerin. Nonsignificant negative association 
was found with omentin and diabetes status. Chemerin is an adipose-tissue derived 
adipocytokine that has been shown to be elevated in states of obesity-related disorders 
such as T2D.19,31-32 Recently, chemerin was identified as a pro-inflammatory 
adipocytokine that plays a role in inflammation and metabolism.33-34 It is therefore 
suggested that chemerin may provide a link between chronic low-grade inflammation and 
T2D. Our findings on chemerin are in contrast to that of El-Mesallamy et al.35 who 
reported that chemerin levels were significantly increased in participants with T2D 
compared to participants without T2D. However, our findings are in line with that of 
Bozaoglu et al.19 which failed to show a significant difference in chemerin levels in 
adults with compared to without T2D. The non-significant difference in chemerin levels 
between participants with and without T2D and the greater effect of association for 
participants without T2D than participants with T2D may be due to the fact that a higher 
proportion of the participants with T2D were on diabetes medications. The medications 
for diabetes have been reported to significantly decrease chemerin levels in diabetic 
patients. For example in a study among women with polycystic ovarian syndrome, 
metformin, an oral hypoglycemic agent, was shown to decrease circulating chemerin 
levels with a simultaneous decrease in insulin resistance.36  
Omentin is a novel polypeptide hormone which triggers Akt/protein kinase B 
phosphorylation and insulin stimulated glucose uptake in human adipocytes in vitro.23 
Omentin is considered an anti-inflammatory modulator and may have a protective role in 
T2D.37 Although our findings demonstrated that participants without T2D had higher 
omentin levels, this association was not significant and might be that a lowering of 
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chemerin levels by diabetes medications caused a reciprocal increase in omentin levels in 
participants with T2D. However, the levels may not have been pronounced to detect a 
significant difference. However, previous studies showed that omentin levels were 
increased in healthy individuals compared with adults with T2D and found a significant 
negative association.35,37-38 The roles of omentin and chemerin in regulating metabolic 
function still need to be fully elucidated in future investigations among drug-free subjects 
to exclude any residual confounding effects of medications.  
Chemerin levels are positively associated with obesity, but negatively associated 
with insulin sensitivity.31,34,39 Chemerin is secreted by mature adipocytes within adipose 
tissue.19 Obesity leads to hypertrophy of adipocytes which in turn increases chemerin 
secretion and contributes to inflammation. Previous studies have shown that chemerin 
may regulate insulin signaling and glucose metabolism.40-41 In vitro studies in 3T3-L1 
adipocytes revealed that chemerin impaired insulin sensitivity and induced insulin 
resistance in muscle cells.41 Impaired insulin sensitivity is a major risk factor for the 
development of T2D. In addition, administration of chemerin to obese diabetic mice 
resulted in decreased tissue glucose uptake and worsened glucose intolerance.32 In 
accordance, serum chemerin levels were positively associated with BMI, although a 
nonsignificant one which might be due to the effect of medications on chemerin levels as 
already discussed above, since most of the obese individuals in our sample also had T2D. 
Other earlier studies also reported no significant association between serum chemerin and 
BMI.34 Additionally, in the present study, chemerin was negatively associated with 
insulin sensitivity, a finding in line with the studies by Kim et al.31 that showed a negative 
association between chemerin and insulin sensitivity in adults with T2D. Other studies 
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have demonstrated conflicting results, with the study by Takahashi et al.41 reporting that 
increased levels of chemerin stimulated insulin sensitivity. Thus, these conflicting 
findings warrants a need to clarify the mechanisms by which chemerin regulates glucose 
homeostasis.31,41 Omentin was negatively associated with BMI and positively associated 
with insulin sensitivity in the present study. Omentin is secreted by the visceral adipose 
tissue and is decreased in obese patients, while it is involved in improving insulin 
sensitivity.23 Recently, in a study conducted by El-Mesallamy35 in Egyptian adults 
comparing omentin levels between those with T2D and healthy controls, omentin levels 
were negatively associated with obesity. Similarly, Tan et al.42 found a negative 
correlation between BMI and omentin levels. However, the nonsignificant differences for 
chemerin and omentin levels found between normal weight, overweight or obese in 
participants without T2D and between overweight and obese individuals in participants 
with T2D might be due to the smaller sample sizes for the normal weight and overweight 
group. It is possible that the significant differences in chemerin and omentin levels found 
between normal weight and obese patients among participants with T2D may have 
occurred by chance.  
We have also demonstrated that Haitian Americans with T2D had significantly 
lower levels of chemerin and significantly higher levels of omentin compared with 
African Americans with T2D. This could be due to the lower BMI and higher insulin 
sensitivity observed in Haitian Americans compared to a higher BMI and impaired 
insulin sensitivity in African Americans. A lower BMI has been associated with 
increased insulin sensitivity which results in lowered insulin resistance.31 Haitian 
Americans without T2D compared to African Americans without T2D, had significantly 
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lower levels of chemerin and surprisingly, slightly lower, but nonsignificant levels of 
omentin. Also in regression analysis, chemerin was associated with African American 
ethnicity which is expected. It is not surprising that the association of Haitian American 
ethnicity with omentin was not significant, which may have been due to low levels of 
omentin found among Haitian Americans. An explanation may be the higher percentage 
of lipid lowering drugs and NSAIDs use by African Americans which decreased 
possibility of significant differences being observed. An alternative explanation may be 
due to differences in particular metabolic characteristics between Haitian Americans and 
African Americans. The influence of certain unique characteristics such as acculturation, 
genetics and other environmental factors cannot be ruled out. The lack of existing data on 
the two ethnicities with regards to chemerin and omentin make it difficult to compare and 
contrast our findings with the literature and draw substantial conclusions. It is necessary 
for additional studies to be conducted in order to make further conclusions.  
The limitation of this study is the cross-sectional nature which did not allow 
causality to be considered. In addition, the study population is a semi-convenience 
sample and not recruited by randomized selection. Moreover, genetic and acculturation 
factors may be possible influential variables on chemerin and omentin that were not 
considered. As such, the sample may not be representative of Haitian Americans and 
African Americans and generalizability to the general population may be limited. The 
serum chemerin levels measured are a reflection of the total level since the ELISA did 
not allow for the chemerin variants to be distinguished. Despite the limitations, this study 
has for the first time assessed novel adipocytokines, chemerin and omentin in two distinct 
non-Hispanic subgroups, which allows important ethnic differences in metabolic 
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processes to be revealed. These results provide new opportunities for designing ethnic 
centered preventive strategies and targets for the treatment of T2D, particularly in non-
Hispanics who are at high risk for T2D and its related complications. The serum levels of 
chemerin and omentin in this study are similar to those found in other studies using the 
same ELISA kit or studies conducted in participants with and without T2D and other 
disorders.35,43-44   
CONCLUSION 
 In conclusion, Haitian Americans with T2D had lower chemerin and higher 
omentin levels compared to African Americans with T2D. These findings support the 
need to conduct studies of metabolic disorders based on ethnicity, particularly for non-
Hispanic Blacks who are highly susceptible to T2D and its associated outcomes. 
Moreover, important factors such as acculturation, genetics and other environmental 
factors may be unique to each ethnic subgroup and influence disease risk factors and 
progression of T2D. The relationship of chemerin and omentin with T2D should be 
further investigated in prospective studies.  
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TABLE 1. Characteristics of the Participants by Diabetes Status 
          Diabetes status                                                     
Variables            With 
            T2D 
    (n = 204) 
    Without  
       T2D 
    (n = 225) 
 
    P-value 
               Overall 
        
               (n = 429)  
Age (years)  56.0±10.2   52.1±9.7  <0.001    53.9±10.1 
Female n (%)        110(53.9)  114(50.7)   0.500    224(52.2) 
Ethnicity                                                                                                               0.593                  - 
               HA n (%)                                       99(48.5)              115(51.1)                 -                                214(49.9)           
               AA n (%)                                     105(51.5)             110(48.9)                 -                                215(50.1) 
*BMI categories (kg/m2)                                                                                      0.009                                  - 
        Normal weight n (% )                          25(12.3)               36(16.0)                 -                                 61(14.2)  
        Overweight n (%)                                58(28.4)               89(39.6)                 -                                147(34.3) 
        Obese n (%)                                       121(59.2)             100(44.4)                 -                                221(51.5) 
Smoke n (%)         42(20.6)  51(22.7)  0.602     93(21.7) 
Lipid lowering drugs n (%)         85(41.7)  24(10.7)  <0.001     109(25.4) 
NSAIDs n (%)         84(41.2)  55(24.4)  <0.001     139(32.4) 
Oral hypoglycemic meds n (%)         168(82.4) -   -     168(39.2) 
A1C (%)          8.1±2.3     6.0±0.8  <0.001     7.0±1.9 
FPG (mmol/L)      150.9±65.1 101.0±23.9  <0.001      124.8±54.2 
Insulin (µIU/mL)        11.8±9.2 11.4±8.2    0.666     11.6±8.7 
HOMA2-IS 
Chemerin (ng/mL)                             
      86.9±50.1 
    334.3±103.2 
93.6±51.9 
348.5±110.1 
   0.181 
   0.170 
     90.5±51.1 
     341.7±107.0 
Omentin (ng/mL)    723.1± 327.4 752.2±315.0    0.349      738.3±320.9 
Data were expressed as mean ± SD unless otherwise indicated. Abbreviations: T2D = type 2 diabetes; HA = Haitian Americans; AA = African 
Americans; BMI = body mass index; NSAIDs = non-steroidal anti-inflammatory drugs; A1C = hemoglobin A1C; FPG = fasting plasma glucose; 
HOMA2-IS = homeostasis model assessment version 2 of insulin sensitivity. *BMI categories: Normal weight: BMI<25kg/m2, Overweight: BMI 
25kg/m2 - <30kg/m2 and Obese: BMI ≥30kg/m2. 
P-value is considered significant at <0.05. 
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TABLE 2. Characteristics of the Participants by Ethnicity and Diabetes Status 
    With T2D                                                          Without T2D 
       Variables Haitian  
American 
(n = 99) 
    African 
  American 
   (n = 105) 
 
P-
value 
   Haitian  
American 
 (n = 115) 
    African 
  American 
   (n = 110) 
 
   P- 
 value 
Age (years) 57.9±9.7    54.2±10.3   0.009  53.7±10.5      50.5±8.5       0.013 
Female n (%)    54(54.5)     56(53.3)   0.862   57(49.6)     57(51.8)  0.735 
*BMI categories (kg/m2)                                                              <0.001                                                                   0.063    
        Normal weight n (%)              22(22.2)               3(2.9)              -                         23(20.0)          13(11.8)             - 
        Overweight n (%)                   38(38.4)             20(19.0)            -                         49(42.6)           40(36.4)            - 
        Obese n (%)                            39(39.4)             82(78.1)            -                         43(37.4)           57(51.8)            -       
Smoke n (%)     5(5.1)      37(35.2) <0.001       7(6.1)      44(40.0) <0.001 
Lipid lowering drugs n (%)   38(38.4)      47(44.8)  0.356    9(7.8)      15(13.6)        0.158 
NSAIDs n (%)   31(31.3)      53(50.5)  0.005   23(20.0)      32(29.1)        0.113 
Oral hypoglycemic meds n (%)   90(90.9)      78(74.3)   0.002   -           -       - 
A1C (%)    8.5±2.6      7.6±1.9  0.009  6.2±0.9      5.9±0.5    0.025 
FPG (mmol/L) 154.2±62.4   147.9±67.7  0.494  105.1±29.0     96.7±15.9    0.008 
Insulin (µIU/mL)    9.4±7.2     14.1±10.3 <0.001   9.9±5.3     12.9±10.2    0.006 
HOMA2-IS                                  100.9±51.9         73.8±44.7      <0.001                   97.9±50.3        89.1±53.4        0.202    
Chemerin (ng/mL)                      310.2±96.9        357.1±104.2    <0.001                318.1±94.9       380.3±116.2    <0.001   
Omentin (ng/mL)                       777.1±367.1       672.1±277.2      0.023                716.3±319.5     789.7±307.3      0.080    
 
Data were expressed as mean ± SD unless otherwise indicated. Abbreviations: T2D = type 2 diabetes; HA = Haitian Americans; 
AA = African Americans; BMI = body mass index; NSAIDs = non-steroidal anti-inflammatory drugs; A1C = hemoglobin A1C; 
FPG = fasting plasma glucose; HOMA2-IS = homeostasis model assessment version 2 of insulin sensitivity.  
*BMI categories: Normal weight: BMI<25kg/m2, Overweight: BMI 25kg/m2 - <30kg/m2 and Obese: BMI ≥30kg/m2. 
P-value is considered significant at <0.05. 
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                   BMI Categories  
                                                                      Participants with T2D 
                            
         Variables                         Normal weight                     Overweight                                 Obese              P- value  
                                                        (n = 25)                               (n = 58)                             (n = 121) 
BMI categories(kg/m2)                    <25                                     25-<30                                   ≥30                       –  
Chemerin (ng/mL)                    292.6±102.1a                        320.0±107.5ab                      349.8±98.7b                   0.030 
Omentin (ng/mL)                      913.1±467.7a                        742.7±306.1ab                      674.4±288.1b           0.002 
                                                                    Participants without T2D 
                            
                                                    Normal weight                     Overweight                                Obese               P-value 
                                                        (n = 36)                              (n = 89)                               (n = 100) 
 
BMI categories (kg/m2)                   <25                        
Chemerin (ng/mL)                     336.7±105.4                
Omentin (ng/mL)                       825.6±367.8               
         25-<30              
       332.4±97.8 
      764.1±303.1        
            ≥30                        –  
      367.2±119.9                      NS 
      715.1±302.6                      NS 
 
        
 
 
 
 
 
Data are expressed as mean ± SD unless otherwise indicated.  P-value is considered significant at <0.05. Abbreviations: T2D = type 2 diabetes; 
BMI = body mass index; NS = no significant differences between normal weight, overweight and obese or overweight and obese individuals.   
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TABLE 4. Association between Chemerin and Diabetes Status – Multiple Linear Regression Analysis 
                              
          Variables                         B 
  
SE                        β                         t                         P-value  
                        
      Diabetes status                  -41.35                18.28                 -0.19                   -2.26                       0.024 
      Ethnicity                             38.48                11.59                  0.18                     3.32                       0.001      
      HOMA2-IS                         -0.23                 0.11                  -0.11                    -2.18                      0.030 
      BMI                                     1.22                  0.86                   0.08                     1.43                       0.153 
      Age                                      1.37                  0.51                   0.13                     2.68                       0.008 
      Gender                              -21.14                10.15                 -0.09                    -2.08                       0.038 
      Smoke                                24.81                13.24                  0.09                      1.87                       0.062 
      Lipid lowering drugs         15.56                12.89                   0.06                      1.21                      0.228 
      NSAIDs                              21.31               11.39                   0.09                      1.87                      0.062 
      Oral hypoglycemic meds    9.39                 19.06                   0.04                      0.49                      0.622 
Adjusted R2 of model: 12.9% of independent contribution of diabetes status (t =-2.26, P=0.024). Abbreviations: HOMA2-IS = 
homeostasis model assessment version 2 of insulin sensitivity; BMI = body mass index; NSAIDs = non-steroidal anti-inflammatory drugs; 
B = unstandardized coefficients; SE = standard error; β = standardized coefficient. P-value is considered significant at <0.05.
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    TABLE 5.  Association between Omentin and Diabetes status – Multiple Linear Regression Analysis 
                              
          Variables                            B 
  
       SE                        β                         t                         P-value  
                        
      Diabetes status                    -85.02                     56.86                 -0.13                    -1.50                     0.136 
      Ethnicity                               52.71                     36.07                  0.08                     1.46                      0.145 
      HOMA2-IS                            0.11                       0.33                   0.02                     0.33                      0.745 
      BMI                                      -6.64                       2.66                  -0.14                    -2.49                     0.013 
      Age                                        6.69                       1.59                    0.21                     4.19                   <0.001 
      Gender                                  15.55                     31.57                   0.02                     0.49                     0.623 
      Smoke                                 -30.92                     41.18                  -0.04                    -0.75                     0.453 
      Lipid lowering drugs            73.80                     40.13                   0.10                     1.84                     0.067 
      NSAIDs                                4.56                       35.43                   0.01                     0.13                     0.898 
      Oral hypoglycemic meds     26.56                     59.29                   0.04                      0.45                     0.654 
Adjusted R2 of model: 6.3% of independent contribution of diabetes status (t =-1.50, P=0.136). Abbreviations: HOMA2-IS = homeostasis 
model assessment version 2 of insulin sensitivity; BMI = body mass index; NSAIDs = non-steroidal anti-inflammatory drugs; B = 
unstandardized coefficients; SE = standard error; β = standardized coefficient.  P-value is considered significant at <0.05.
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CHAPTER V: ASSOCIATION OF LEPTIN WITH BMI AND INSULIN RESISTANCE 
IN HAITIAN AND AFRICAN AMERICANS WITH AND WITHOUT TYPE 2 
DIABETES 
ABSTRACT  
Background: Obesity has become a worldwide epidemic and non-Hispanic Blacks are 
disproportionately affected. Leptin is an adipose tissue derived peptide that is considered 
both structurally and functionally as a pro-inflammatory adipocytokine. Leptin has been 
associated with obesity, insulin resistance and type 2 diabetes (T2D). Ethnic differences 
in metabolic profile even within the same ethnicity may affect leptin levels and disease 
outcomes. The purpose of our study was to determine the variation in serum leptin levels 
in Haitian and African Africans and assess the association of leptin levels with body mass 
index (BMI) and insulin resistance. Methods: In 413 participants, 213 Haitian Americans 
and 200 African Americans (197 with T2D and 216 without T2D), fasting blood samples 
and clinical data were obtained, and socio-demographic data were collected using 
standardized questionnaires. Serum leptin levels and insulin resistance measures were 
analyzed by ELISA and HOMA-2-IR, respectively.   Results: The serum log leptin levels 
in Haitian American males and females were significantly lower (P<0.05) than those in 
African American males and females. Haitian Americans with T2D had significantly 
lower serum log leptin levels (P=0.024) than did African Americans with T2D. Log 
leptin levels were significantly associated with BMI (P<0.001) and HOMA2-IR 
(P=0.015) in males without T2D, whereas in males with T2D and females with and 
without T2D, leptin was associated with only BMI (P<0.001) as a primary independent 
variable. Conclusion: The lower leptin levels in Haitian Americans may be due to 
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favorable metabolic profile including lower obesity and insulin resistance. The ethnic 
differences may also be attributable to genetic variation and differences in lifestyle, 
environmental and acculturation factors which may affect risk of disease. Future studies 
should focus on the association of these factors with leptin levels in the two ethnic 
subgroups. In addition, these findings may help identify individuals at risk for T2D 
across adiposity and make an important contribution in designing ethnic centered 
interventions to prevent T2D.  
  
INTRODUCTION 
 Obesity, defined as body mass index (BMI) of ≥30 kg/m2, has become a major 
health concern.1-3 Approximately, one-third of the United States adult population is 
obese.3 Between 1997-2007 and 2011-2012, there has been a significant increase in the 
prevalence of obesity from 27% to 35% for both men and women and across all age 
groups.3-4 Obesity is one of the major causes of preventable death and is closely related to 
insulin resistance, which may lead to type 2 diabetes (T2D).2,5-7 Type 2 diabetes is a 
major cause of morbidity and mortality in the United States.8 Type 2 diabetes and its 
health-related outcomes pose an immense burden both on individuals with the disease 
and on public health systems.9 The prevention of T2D and its associated outcomes, 
particularly cardiovascular risk has become a public health priority. Anti-diabetes efforts 
to reverse the increasing prevalence of T2D is threatened by a growing epidemic of 
obesity.2 While insulin resistance is widely accepted as the core process in the 
development of T2D, new concepts indicate initial inflammatory responses.10-11 Several 
peptides released from white adipose tissue with excess adiposity have been implicated in 
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the coexistence of obesity and T2D. Leptin is one of the peptides that influences energy 
intake, inflammation and insulin resistance.12-13  
  Leptin an adipocytokine and a product of the ob gene regulates body weight by 
acting centrally to reduce energy intake.14-17 Additionally, leptin modulates glucose and 
fat homeostasis.12,15 In humans, circulating levels of leptin are directly proportional to 
BMI or body fat percentage and high levels of leptin in obese individuals suggests leptin 
resistance in the central nervous system.15,18 Previous studies show that obesity-induced 
leptin resistance activates the c-Jun NH(2)-terminal kinase (JNK) and inhibitor of nuclear 
factor kappa-B kinase subunit beta (IKKβ) inflammatory pathways.13 Moreover, leptin 
has structural similarity to interleukin-6 (IL-6) and may subsequently increase C-reactive 
protein (CRP) levels.19-21 Further, leptin stimulates macrophages and monocytes to 
produce IL-6 and TNF-α, pro-inflammatory adipocytokines well-recognized to affect 
insulin sensitivity and induce insulin resistance.20 The reports of associations of leptin 
with other pro-inflammatory adipocytokines, insulin resistance and prevalence of T2D 
indicate leptin as a strong determinant of obesity and its complications.22 Serum leptin 
levels also show marked gender differences, with higher concentrations in women than in 
men at all levels of BMI.23 Apart from gender, existing studies also show that lifestyle 
factors such as diet and smoking may affect serum leptin levels.22,24-25 For example, 
vitamin D is an immune-modulator which may attenuate inflammation, enhance insulin 
sensitivity and thus is inversely associated with leptin levels.25 Cigarette smokers, on the 
other hand have lower leptin levels compared to their non-smoking counterparts.22,24  
 A number of population-based studies have consistently shown that compared 
with non-Hispanic Whites, non-white ethnicities, particularly non-Hispanic Blacks have 
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high prevalence of obesity, insulin resistance and T2D.26 It is suggested that the ethnic 
differences in these metabolic-related factors is partly explained by differences in 
adiposity and body composition.1-3 Extensive research on ethnic differences in pro-
inflammatory adipocytokines such as CRP and IL-6 linking adiposity, insulin resistance 
and T2D have been conducted.27-29 Moreover, only a few epidemiological studies have 
reported ethnic differences in leptin levels24,30-31 and such studies are yet to be conducted 
among non-Hispanic Blacks. In addition, previous studies on leptin levels in individuals 
with T2D are also controversial.32-34 Leptin levels were found to be lower in obese 
individuals with T2D, whereas other data show increased or unchanged levels in these 
individuals. 
 In the current study, we investigated; 1) ethnic variation of leptin levels in Haitian 
and African Americans with and without T2D and 2) the association of leptin with BMI 
and insulin resistance controlling for important confounders including diet and lifestyle 
factors.  
 
METHODS 
Participants and Study Design 
This was a cross-sectional study conducted in Haitian and African Americans 
with (n= 197) and without (n = 216) T2D. The study protocol was approved by the 
Institutional Review Board at Florida International University (FIU). Within a period of 
one year, about 7550 letters were mailed to African Americans in South Florida, from the 
Miami-Dade and Broward Counties to request their participation. The list of mailing 
addresses for African Americans with and without T2D was purchased from the 
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Knowledge Base Marketing, Inc., Richardson, TX, USA. Of the letters mailed, 4% (n = 
256) of the participants responded. Due to unavailability of similar database of mailing 
addresses for Haitian Americans, recruitment for this group was done through multiple 
community based sources. These sources included local diabetes educators and 
community health practitioners, and staff, faculty and students of FIU. In addition, 
advertisements were placed in local Haitian supermarkets, churches, and restaurants and 
announcements were aired on Creole radio stations. Respondents were interviewed on 
phone. The purpose of the study was fully explained and the age (≥35 years), gender and 
self-identified ethnicity (Haitian American or African American) were assessed. For 
respondents who self-reported as having T2D, initial treatment modalities, duration of 
diabetes and fasting plasma glucose (FPG) and glycated hemoglobin levels (A1C) were 
obtained. Exclusion criteria included kidney failure, hepatitis, HIV and cancer. Eligible 
participants were requested to enroll in the study at the Human Nutrition Laboratory at 
FIU. Participants to enroll in the study were instructed to fast at least 8 hours prior to 
their blood collection. Additionally, they were instructed to refrain from smoking and any 
unusual exercise, but could drink only water. Written informed consent in English or 
Creole was obtained from each participant after they understood the requirements on the 
form. The laboratory results of twelve participants (8 Haitian Americans and 4 African 
Americans) who reported not having T2D revealed high values for FPG and A1C and 
were reclassified as having T2D. These individuals were referred to their physicians. 
Participants (n = 103) with missing values and outliers for leptin, HOMA2-IR, serum 
vitamin D {25(OH)D} and energy intake were excluded. A total of 413 participants, 197 
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with T2D and 216 without T2D (213 Haitian and 200 African Americans) were included 
in all data analysis. 
Socio-demographic data 
 A standardized self-reported questionnaire was used to obtain information 
regarding age, gender, smoking status, and medications used. Self-reported information 
on ethnicity was confirmed during interview. Anthropometric measures were obtained at 
the Human Nutrition Laboratory. Height and weight were measured with the SECA 
balance scale (Seca Corp, Columbia, MD). Body mass index (BMI) was calculated as 
weight in kg divided by height in m2. 
Assessment of dietary intake 
 The validated and standardized Harvard semi-quantitative food frequency 
questionnaire was used to obtain information on macro- and micro-nutrients from foods 
and vitamins consumed. Participants self-reported average intake of specified quantities 
of foods over the past year. Daily servings for food groups were calculated by totaling 
frequency scores for all food items. The output of these calculations were used to obtain 
the energy intake (kcal) of participants.  
Blood collection and laboratory measurements 
Twenty milliliters of venous blood was collected in a Vaccutainer Serum 
Separator tubes by a trained and certified phlebotomist using standard methods, following 
an 8-hour overnight fast. Blood samples were centrifuged at 2500 RPM for half an hour 
after coagulation. The separated serum was aliquoted into 3 labeled plastic tubes. Two 
were designated for analysis of glucose and vitamin D. The third aliquot was stored at -
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700C for subsequent analyses. Glucose levels were measured by hexokinase enzymatic 
methods (Laboratory Corporation of America, FL, USA). Hemoglobin A1C percentages 
were assayed in whole blood samples applying the Roche Tina Quant method 
(Laboratory Corporation of America, FL, USA). Serum vitamin D (25(OH)D) levels 
were determined with a commercial enzyme linked immunosorbent assay kit (ELISA) 
from Immunodiagnostic Systems Limited (Scottsdale, AZ, U.S.).  
Leptin levels in serum were measured at the Human Nutrition Laboratory at FIU 
using ELISA developed with monoclonal antibody specific for leptin pre-coated onto a 
microplate, according to manufacturer’s protocol (R&D Systems, Minneapolis, MN, 
USA). Briefly, 100µl of Assay Diluent RD1-19 was added to each well followed by 
100µl of standards, dilution buffer (blank) and diluted samples (100x – 10µl sample plus 
990µl dilution buffer). After 2 hours of incubation at room temperature followed by 
washing, 200µl of leptin conjugate was added and incubated with the bound leptin for an 
hour. After a second washing step, 200 µl substrate solution was added and incubated for 
half an hour to allow reaction with the residual conjugate. The reaction process was 
stopped by addition of 50 µl of N sulfuric acid stop solution. The absorbance of the 
resulting product was measured at 450nm with a spectrophotometer. A microplate reader 
capable of creating a standard curve plotted the mean absorbance values against the leptin 
concentrations of standards. The software used the standard curve to determine the 
concentrations of the unknown diluted samples multiplied by the dilution factor to obtain 
the actual amount of serum leptin. The sensitivity of the ELISA assay was 7.8 pg/ml and 
the range was 7.8–1000 pg/ml (78–100000 pg/ml with dilution factor). The intraassay 
and interassay coefficients of variation were both less than 10%.  
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Calculation of insulin resistance (HOMA2-IR) 
The Oxford University HOMA2 calculator was used to calculate insulin 
resistance as previously described.35 The model determines insulin resistance (HOMA2-
IR) from paired fasting plasma glucose and radioimmunoassay insulin across a range of 
1-2,200 pmol/l for insulin, and 1-25 mmol/l for glucose.  
Data Analysis 
All statistical analyses were conducted with SPSS version 21 (IBM Corporation, 
Chicago, IL, USA). The Kolmogorov-Smirnov test was used to assess the normality of 
the distribution of the data. The distributions of leptin and insulin resistance (HOMA2-
IR) were natural log-transformed to improve normality. All data analyses were separated 
by gender because the mean serum leptin levels differed by gender in our sample. 
Moreover, gender was an independent predictor of leptin levels in previous studies.23 
Differences in mean values between ethnicity and diabetes status were compared by 
Student’s t-test for continuous variables and χ2 tests for categorical variables. The 
relationships between variables were analyzed by multiple linear regression using log 
leptin as the dependent variable. The models were generated separately for diabetes status 
and gender. Independent variables including BMI and HOMA2-IR as primary predictors, 
age, ethnicity (Haitian American/African American), smoke status (yes/no), energy 
intake, serum 25(OH)D, lipid lowering drugs (yes/no), nonsteroidal anti-inflammatory 
drugs (NSAIDs) (yes/no) were forced into the model. For all analyses, a P-value of <0.05 
was considered to be statistically significant. 
 
 
 104 
 
RESULTS  
 Of the 413 Haitian and African Americans with and without T2D, 49.9% were 
males and 50.1% were females. The general demographic and health-related 
characteristics of the study population by ethnicity are shown in Table 1. Compared with 
Haitian Americans, African Americans were younger (P<0.05) and had a higher 
percentage of smokers (P<0.001). African American females had higher mean BMI 
(35.1±8.3 vs. 29.9±5.0, P<0.001), were more obese (P=0.003), had higher energy intake 
(P=0.045), lower serum vitamin D levels (P=0.005), higher log HOMA2-IR (P=0.014) 
and higher log leptin levels ((P=0.029) than did Haitian American females. While the 
mean serum vitamin D levels (60.3±26.9 vs. 54.0±19.7, P=0.060) were higher in African 
American males, although not significantly, the mean BMI (31.2±6.0 vs. 28.1±4.2, 
P<0.001), obesity (P<0.001), energy intake (P<0.001), log HOMA2-IR (P=0.004) and 
log leptin levels (P=0.001) were significantly lower in Haitian American males. With the 
exception of significantly higher use of NSAIDs (P<0.001) among African American 
females compared to Haitian American females, there was no significant ethnic 
difference in the use of lipid lowering drugs and oral hypoglycemic medications between 
males and females.  
  The general demographic and health-related characteristics of the study 
population by diabetes status are shown in Table 2. BMI was significantly higher in 
males and females with T2D compared to those without T2D (P<0.05), however, no 
significant difference was observed for percentages of obese males and females with and 
without T2D. Energy intake was significantly lower among males with T2D compared to 
males without T2D (P<0.001), but no difference was seen in females. Although low 
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serum vitamin D levels were common in females with compared to those without T2D 
(P=0.045), no significant difference was observed in males. As expected, the use of lipid 
lowering drugs (P<0.001), NSAIDs (P<0.05) and oral hypoglycemic medications 
(P<0.001) were significantly higher among males and females with T2D compared to 
males and females without T2D. Both males and females with and without T2D had 
similar tendencies to smoke. The mean log leptin and mean log HOMA2-IR were not 
significantly different between males and females with and without T2D.  
 A test of the means by Student’s t-test showed a significant difference in serum 
log leptin levels by males and females, obesity and ethnicity/diabetes status in the entire 
sample (data not shown). Males had significantly lower mean log leptin levels as 
compared to females (9.3±0.9 vs. 10.4±0.8, P<0.001). Obese individuals had significantly 
higher mean log leptin levels compared with non-obese individuals (10.4±0.8 vs. 9.4±0.9, 
P<0.001). In addition, Haitian Americans with T2D, contrary to our earlier hypothesis, 
had lower mean log leptin levels compared to African Americans with T2D (9.6±1.2 vs. 
10.1±0.8, P=0.001). 
 Tables 3 and 4 show the results of multiple linear regression analyses conducted 
using serum log leptin levels as the dependent variable. In males with T2D, log levels of 
leptin were predicted by ethnicity, age and BMI, whereas in males without T2D, BMI 
and log HOMA2-IR were the major determinants. In females with T2D, changes in log 
leptin levels were explained by BMI and log HOMA2-IR had a slight trend towards 
significance. However, in females without T2D, BMI and smoking explained serum log 
leptin levels, and ethnicity had a slight trend towards significance. Overall, BMI was the 
strongest predictor of serum log leptin levels across all groups. These results reinforce 
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existing evidence that serum log leptin levels in males are altered differently from those 
of females. The differences in predictors of serum leptin levels between participants with 
and without T2D may suggest T2D as an influential factor in our sample. Independent 
variables for males with T2D and without T2D, females with T2D and without T2D 
explained 44%, 61%, 18% and 33% of the variance of log leptin levels in separate 
regression models, respectively. Energy intake, serum vitamin D and medications were 
not significantly associated with log leptin levels.   
 
DISCUSSION 
 In the present study, we evaluated serum leptin levels in Haitian and African 
Americans with and without T2D. We observed significant differences in serum leptin 
levels across ethnic groups by gender, but not with diabetes status by gender. Haitian 
American males and females had lower serum leptin levels compared to African 
American males and females. Among the diabetes groups, the nonsignificant difference 
in serum leptin levels in participants with and without T2D is consistent with other 
research.36 A number of factors may explain the nonsignificant difference observed: 
firstly, advancing disease may cause continuing loss of the normal processes of leptin 
regulation.36 Secondly, adiposity and gender are the main predictors of leptin levels in 
both individuals with and without T2D. A difference in distribution of adipose tissue 
accumulation, where subcutaneous fat has been shown to produce more leptin compared 
to visceral fat.37-38 Individuals with T2D have been shown to have more visceral and less 
subcutaneous adipocytes;38 although this was not determined in our study.  Females with 
T2D had lower leptin levels compared to females without T2D, whereas males with T2D 
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had higher leptin levels than males without T2D, although nonsignificantly in both 
instances. Thirdly, medications used in the treatment of T2D may reduce the leptin levels 
in individuals with T2D. For instance, in a randomized clinical trial, metformin and 
pioglitazone, two commonly used oral hypoglycemic medications reduced leptin levels in 
individuals with newly diagnosed T2D.39 The lack of conclusive data regarding the levels 
of leptin in individuals with T2D warrants further research among newly diagnosed drug-
free T2D individuals.  
As expected, in our study, we found that leptin was strongly associated with BMI, 
a globally accepted surrogate of general adiposity, in all groups. Our sample was made up 
of overweight (on the higher side) and obese individuals, thus the results observed is not 
unexpected. Leptin is primarily an adipose-tissue derived peptide and the first identified 
adipocytokine.13 Leptin regulates food behavior and energy expenditure and interacts 
with inflammatory pathways and immune function.12,14,18-21 An autosomal recessive 
mutation of the obese gene (ob) results in increased food intake and obesity.15 Thus, 
increased levels of leptin signifying leptin resistance in obesity is the key feature of the 
strong positive relationship between leptin with BMI and adipose mass. Leptin resistance 
and the accumulation of adipose mass results in inflammatory responses in adipose 
tissue. Leptin induces inflammation through key inflammatory pathways including JNK 
and IKKβ.18 Moreover, with a similar structure to IL-6, leptin induces inflammatory 
response through its proximal Janus kinase 2 (JAK2) signaling pathway and as such may 
modulate C-reactive protein.19-21 Leptin also activates innate and adaptive immunity 
which causes macrophages and monocytes to produce the pro-inflammatory 
adipocytokines, IL-6 and TNF-α.20 Together, all these processes of leptin lead to insulin 
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resistance in peripheral tissues. Various researchers have suggested that leptin may 
actually be the link between obesity, insulin resistance and the development of T2D.22 In 
our entire sample, obese individuals had significantly higher levels of leptin than non-
obese individuals. The strong positive relationship of leptin with BMI found in our 
sample is in agreement with those reported by previous studies for overweight/obese 
participants with and without T2D.33-34,36,40 
 Type 2 diabetes is a disease of leptin and insulin-mediated signaling pathways.41 
Leptin and insulin levels are directly interrelated with body weight and adipose mass. 
Leptin attenuates insulin action and insulin signaling.18-21 However, the literature is 
inconsistent regarding circulating leptin levels and insulin resistance. As mentioned, 
gender difference may partially contribute to the discrepancies in our results. While some 
studies have shown significance for the association between leptin and insulin resistance 
in both males and females,42 others reported that leptin levels are associated with insulin 
resistance independently of BMI only in males.43-44 Our study demonstrated that leptin 
levels were significantly associated with insulin resistance (assessed by HOMA2-IR), 
independently of BMI in males without T2D. However, in males with T2D and females 
with and without T2D, only BMI was associated with levels of leptin after controlling for 
confounders. Similarly, Hattori et al.45 reported that in a sample of 64 Japanese with and 
without T2D, leptin levels were associated with insulin resistance independently of BMI 
in both males with and without T2D. The authors stated that in females, only BMI was 
associated with leptin levels. They concluded that the association between insulin 
resistance and leptin levels in females is dependent on BMI since insulin resistance was 
highly correlated with BMI in their sample. The reason of the differences by gender is 
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proposed to be due to the regulation of leptin levels by the effect of sex hormones which 
are triggered to control body weight.44,46 The nonsignificant association of HOMA2-IR 
with leptin levels in males with T2D in our study, contrary to that observed by Hattori et 
al.45 may be due to the use of diabetes medications in males with T2D. An alternative 
explanation may be the nonsignificant difference in obesity, comparable serum vitamin D 
levels and the higher dietary energy intake among males without T2D.  
  Leptin levels were significantly higher in African American men and there was a 
slight trend toward significance (P=0.088) in African American women in regression 
analysis. Higher proportions of BMI, higher HOMA2-IR, higher dietary energy intake 
and lower serum levels of vitamin D among African American males and females 
compared to Haitian American males and females may account for the observed higher 
levels of leptin in African American males and females. Ethnic comparative studies have 
demonstrated higher levels of leptin in ethnic populations with the highest prevalence of 
metabolic risk factors.24,30-31 African Americans have consistently been shown to have 
higher obesity and insulin resistance compared to non-Hispanic Whites and other 
minorities including the non-Hispanic Black subgroup of Haitian Americans.26,47 The 
greater influence of adiposity in ascertaining the levels of leptin in females, particularly 
among African American women who had the highest proportion of obesity in the current 
study may be applicable to the gender-based difference. Among African Americans, 
particularly African American women, obesity is well accepted and their view of an ideal 
body weight has been significantly higher compared to non-Hispanic Whites.48-49 
Although data is lacking in Haitian Americans, available evidence shows that they are 
less obese and moreover have fewer metabolic abnormalities compared to African 
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Americans.47 The observed ethnic subgroup differences in the risk factors may also 
reflect an interplay of behavioral and lifestyle, genetic and acculturation factors which 
warrant further investigations.    
Regression analyses revealed that socio-demographic and lifestyle factors such as 
age and smoking were positively and inversely associated with leptin levels in men with 
T2D and women without T2D, respectively. Similar to the study conducted by Schautz et 
al.50 leptin levels were increased as an individual ages. A possible explanation may be the 
age-related metabolic decline which alters fat distribution, obesity and insulin resistance. 
The inverse association between smoking and leptin levels may be due to a possibility of 
nicotine to increase sensitivity of insulin dependent tissues to leptin.22,24  
 The cross-sectional design of our study limits us from establishing causality 
between ethnicity, obesity, insulin resistance and T2D with leptin levels. In addition, 
genetic variation and differences in lifestyle, environmental and acculturation factors 
which have the possibility to alter leptin levels between Haitian and African Americans 
were not determined in this study. Although this study used HOMA2-IR an estimate of 
insulin resistance rather than the gold standard of hyperinsulinemic-euglycemic clamp, 
the HOMA2-IR has been used in several cross-sectional studies and has been shown to be 
a reliable surrogate in determining measures of insulin resistance.51 The semi-
convenience nature of our sample is not representative of Haitian and African Americans 
and thus, limits generalizability to the larger population.  
The strength of our study is that we are the first to report gender differences in 
leptin levels in two non-Hispanic Black ethnic subgroups. Our results show that serum 
leptin levels are influenced differently in women compared to men. While the 
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relationship between metabolic risk factors and leptin levels in African Americans have 
been extensively reported in the literature, however, information for Haitian Americans is 
lacking. Thus, this study has not only generated data on this relationship in Haitian 
Americans, but also highlights the need to target these non-Hispanic Black ethnic 
subgroups separately considering the profound differences in metabolic risk factors.    
 
CONCLUSION 
 In conclusion, our results showed that in males without T2D, both BMI and 
HOMA2-IR were independently associated with leptin levels while in males with T2D 
and females with and without T2D, only BMI one of the primary independent variables 
was associated with leptin levels. Further, contrary to our earlier hypothesis, we found 
leptin levels to be lower in Haitian Americans with T2D irrespective of gender compared 
to African Americans with T2D. The lower leptin levels in Haitian Americans may be 
due to favorable metabolic profile including lower obesity and insulin resistance. The 
ethnic differences may also be attributable to genetic variation and differences in 
lifestyle, environmental and acculturation factors which may affect risk of disease. Future 
studies should focus on the association of these factors with leptin levels in the two 
subethnic groups. In addition, these findings may help identify individuals at risk for T2D 
across adiposity level and make an important contribution in designing ethnic centered 
interventions to prevent T2D in this population.  
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            TABLE 1.  Characteristics of the Participants by Sex and Ethnicity  
   Male                                                                  Female 
           Variables  Haitian  
American 
(n = 104) 
    African 
  American 
   (n = 102) 
 
   P-        
 value 
    Haitian  
 American 
 (n = 109) 
 African 
American 
 (n = 98) 
 
     P- 
   value 
     Age (years) 54.9±9.8     51.9±7.8   0.014   56.9±10.9   53.8±10.8          0.043 
     Diabetes status                                                                                 0.582                                                                    0.924       
                 With T2D n (%)              47(45.2)             50(49.0)                                       53(48.6)            47(48.0) 
                 Without T2D n (%)         57(54.8)             52(51.0)                                       56(51.4)            51(52.0) 
    BMI (kg/m2)                                28.1±4.2             31.2±6.0          <0.001                 29.9±5.0           35.1±8.3          <0.001 
    Obese (BMI ≥30 kg/m2)                                                                 <0.001                                                                     0.003     
                  Yes n (%)                       32(30.8)              58(56.9)                                      56(51.4)             70(71.4) 
                   No n (%)                       72(69.2)              44(43.1)                                      53(48.6)             28(28.6) 
    Smoke n (%)                                11(10.6)              51(50.0)           <0.001                 1(0.9)                30(30.6)         <0.001 
    Energy intake (kcal/d)              1844.0±1161.3   2759.0±1846.1    <0.001        1821.3±1074.4      2201.7±1561.6     0.045 
    25(OH)D (nmol/L)                     54.0±19.7           60.3±26.9            0.060               56.2±18.3             48.6±19.8       0.005 
    Lipid lowering drugs n (%)          22(21.2)             27(26.5)             0.370                25(22.9)                32(32.7)        0.118 
    NSAIDs n (%)                              26(25.0)       33(32.4)    0.243      26(23.9)   46(46.9)        <0.001 
    Oral hypoglycemic meds n (%)   42(40.4)    35(34.3)            0.368      48(44.0)   40(40.8)    0.640 
    A1C (%)                                       7.4±2.4      6.7±1.7 0.028       7.1±1.9    6.8±1.7    0.294 
    FPG (mmol/L)                            130.2±58.6  122.7±53.5    0.343  125.6±48.1 121.8±55.0    0.600 
    Insulin (µIU/mL)                          8.8±5.1    12.9±11.1 0.001      10.8±7.1   13.9±9.8 0.011 
    log HOMA2-IR                            0.1±0.5               0.3±0.7              0.004                 0.2±0.5               0.5±0.             0.014      
    log Leptin (pg/mL)                       9.1±0.9               9.6±0.9              0.001                10.3±0.9            10.7±0.7           0.029      
 
Data were expressed as mean ± SD unless otherwise indicated. Abbreviations: T2D = type 2 diabetes; BMI = body mass index; 
NSAIDs = nonsteroidal anti-inflammatory drugs; A1C= hemoglobin A1C; FPG = fasting plasma glucose; HOMA2-IR = homeostasis 
model assessment version 2 of insulin resistance. P-value is considered significant at <0.05. 
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           TABLE 2.  Characteristics of the Participants by Sex and Diabetes Status 
       Male                                                     Female 
        Variables    With  
   T2D 
 (n = 97) 
Without 
    T2D 
(n = 109) 
 
       P-   
    value 
     With  
     T2D 
  (n = 100) 
   Without 
       T2D 
    (n = 107) 
  
        P- 
      value 
     Age (years)  55.9±9.1  51.1±8.2     <0.001  57.1±11.0      53.9±10.7         0.035 
     Ethnicity                                                                                       0.582                                                                   0.924        
                 HA n (%)                        47(48.5)           57(52.3)                                      53(53.0)           56(52.3) 
                 AA n (%)                        50(51.5)           52(47.7)                                      47(47.0)           51(47.7) 
     BMI (kg/m2)                              30.4±5.6           28.9±5.1             0.043                33.9±8.2          30.9±5.9            0.004 
     Obese (BMI ≥30 kg/m2)                                                                0.062                                                                   0.081       
                  Yes n (%)                      49(50.5)            41(37.6)                                      67(67.0)           59(55.1) 
                   No n (%)                      48(49.5)            68(62.4)                                      33(33.0)           48(44.9) 
    Smoke n (%)                              27(27.8)             35(32.1)             0.504                14(14.0)          17(15.9)             0.704 
    Energy intake (kcal/d)           1885.65±1254.8  2663.2±1784.9   <0.001        1826.9±1147.8    2164.4±1480.6      0.070 
    25(OH)D (nmol/L)                     55.8±22.9         58.3±24.5           0.445               49.8±21.5       55.2±16.9            0.045 
    Lipid lowering drugs n (%)         38(39.2)           11(10.1)           <0.001                44(44.0)          13(12.1)           <0.001 
    NSAIDs n (%)                             37(38.1)    22(20.2)      0.004     44(44.0)     28(26.2)         0.007 
    Oral hypoglycemic meds n (%)  77(79.4)          -                     -     88(88.0)          -           - 
    A1C (%)                                      8.2±2.5    6.0±0.8  <0.001     7.9±2.2      6.1±0.7      <0.001 
    FPG (mmol/L)                         154.5±67.6  101.6±24.2     <0.001  148.1±61.0  101.0±23.9     <0.001 
    Insulin (µIU/mL)                        10.6±8.9  11.1±8.8       0.688    12.7±9.4    11.8±7.8        0.429 
    log HOMA2-IR                           0.2±0.6            0.2±0.6               0.599                0.4±0.6            0.3±0.6               0.115      
    log Leptin (pg/mL)                      9.4±0.9            9.3±0.8               0.532               10.4±0.9         10.5±0.7               0.302 
 
Data were expressed as mean ± SD unless otherwise indicated. Abbreviations: T2D = type 2 diabetes; HA = Haitian Americans; 
AA = African Americans; BMI = body mass index; NSAIDs = nonsteroidal anti-inflammatory drugs; A1C = hemoglobin A1C; 
FPG = fasting plasma glucose; HOMA2-IR = homeostasis model assessment version 2 of insulin resistance. P-value is 
considered significant at <0.05. 
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         TABLE 3. Relationship of Leptin with BMI and HOMA2-IR in Participants with T2D – Multiple Linear        
                            Regression Analysis  
          
                                                                   Male (n = 97)                                           Female (n= 100) 
                                     
        Variables                                B             SE             P-value                    B              SE              P-value 
                        
         BMI                                      0.113        0.017          <0.001                   0.055         0.013            <0.001           
        HOMA2-IR                         -0.217        0.134            0.109                  -0.268         0.142              0.063 
        Ethnicity                               0.548        0.212            0.011                  -0.006         0.206              0.977 
        Age                                       0.035        0.010            0.001                  -0.002         0.008              0.838 
        Smoke                                 -0.093        0.200            0.644                    0.077         0.255              0.762 
        Energy intake                       0.000        0.001            0.178                    0.000          0.001              0.986 
        25(OH)D                             -0.005        0.003            0.133                    0.001         0.004              0.948 
        Lipid lowering drugs            0.334        0.168            0.050                    0.079         0.177              0.656 
        NSAIDs                               -0.235        0.172            0.176                    0.104         0.183              0.572 
Abbreviations: BMI = body mass index; HOMA2-IR = homeostasis model assessment version 2 of insulin resistance; NSAIDs = nonsteroidal 
anti-inflammatory drugs; B = unstandardized coefficients; SE = standard error. Leptin and HOMA2-IR were natural log transformed. 
P-value is considered significant at <0.05.
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         TABLE 4. Relationship of Leptin with BMI and HOMA2-IR in Participants without T2D – Multiple Linear      
                            Regression Analysis  
          
                                                                       Male (n = 109)                                           Female (n= 107) 
                                     
        Variables                                     B            SE             P-value                    B              SE              P-value 
                        
         BMI                                          0.111        0.012            <0.001                  0.058        0.011            <0.001 
        HOMA2-IR                              0.240        0.097              0.015                 -0.032        0.118              0.786 
        Ethnicity                                   0.125        0.127              0.326                  0.225        0.131              0.088 
        Age                                           0.012        0.007              0.110                  0.005        0.005              0.397 
        Smoke                                     -0.186        0.132              0.162                 -0.712        0.184            <0.001 
        Energy intake                           0.000        0.001              0.311                  0.000         0.001              0.239          
        25(OH)D                                - 0.002        0.002              0.448                  0.003        0.003              0.440 
        Lipid lowering drugs                0.130        0.200              0.516                  0.108        0.189              0.569 
        NSAIDs                                    0.105        0.152              0.489                 -0.048        0.140              0.732 
Abbreviations: BMI = body mass index; HOMA2-IR = homeostasis model assessment version 2 of insulin resistance; NSAIDs = nonsteroidal 
anti-inflammatory drugs; B = unstandardized coefficients; SE = standard error. Leptin and HOMA2-IR were natural log transformed. 
P-value is considered significant at <0.05.
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CHAPTER VI: SUMMARY AND FUTURE RESEARCH 
The overall primary purpose of the current study was to examine the relationship 
of adipocytokines with metabolic syndrome (MetS), anthropometric and HOMA2 
measures by ethnicity and diabetes status in Haitian and African Americans. The 
involvement of adipocytokines in inflammatory response and metabolic regulation, the 
association of adipocytokines with adiposity and consequently development of MetS and 
T2D, and the high susceptibility of non-Hispanic Blacks for inflammation illustrated in 
the literature initiated this research assessing the effects of adipocytokines in processes 
leading to metabolic disorders such as T2D.  
The altered levels of pro- and anti-inflammatory adipocytokines due to constant 
stimulation of the innate immune system has been suggested as the basis for chronic low-
grade inflammation. It is proposed that this alteration is pronounced with increasing 
adiposity as seen in obese individuals and restored with weight loss. Although the 
mechanisms accountable for adipocytokines in metabolic disorders are not completely 
elucidated, it is thought that altered adipocytokine levels which favor pro-inflammatory 
adipocytokines impair insulin secretion in pancreatic β cells, in addition to perturbation 
of insulin signaling pathways leading to development of T2D. The measurement of 
adipocytokine levels allowed an assessment of inflammation, and their relationship to 
obesity, insulin resistance, MetS and T2D. The dissertation comprised of three studies 
that were built on data from the parent study.  
Explorations of the associations of the pro-inflammatory adipocytokines IL-6 and 
CRP with MetS and its components showed that CRP, but not IL-6 was positively 
associated with MetS after adjusting for important confounders. This partially supported 
 122 
 
our hypothesis that higher levels of IL-6 and CRP will be associated with having MetS. 
Notwithstanding, the current findings support others that have shown the uniqueness of 
CRP as an established and strong predictor of MetS. A lack of association between IL-6 
and MetS has been reported in previous studies. However, the inverse direction found in 
our study may be due to the tight connection of IL-6 with adiposity. Where, lipid 
lowering drugs may have caused a decrease in adiposity and dampened the association of 
IL-6 with MetS. Our earlier hypothesis that Haitian Americans with T2D will have higher 
IL-6 and CRP levels compared to African Americans was found to be the reverse. Higher 
levels of both IL-6 and CRP were associated with African American ethnicity, however 
there was no association with diabetes status. Favorable metabolic factors such as lower 
BMI, waist circumference, insulin resistance and others including acculturation, genetic 
and lifestyle factors in Haitian Americans may have contributed to these findings. 
Findings of the relationship between novel adipocytokines, chemerin and omentin 
with insulin sensitivity, ethnicity and diabetes status showed significant ethnic 
differences for chemerin between ethnic groups, with Haitian Americans having the 
lowest chemerin levels compared to African Americans. Omentin levels did not differ 
significantly between Haitian and African Americans. Moreover, there was no significant 
difference in either chemerin or omentin levels by diabetes status. However, analyses of 
these adipocytokines stratified by both ethnicity and diabetes status showed that Haitian 
Americans with T2D had lower chemerin and higher omentin levels than African 
Americans with T2D. Linear regression models generated with chemerin and omentin as 
separate dependent variables showed that chemerin was inversely associated with insulin 
sensitivity and positively associated with African American ethnicity and diabetes status. 
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Omentin on the other hand was positively associated with insulin sensitivity and 
negatively associated with being African American and diabetes status. Apart from a 
most likely explanation of Haitian Americans possessing advantageous characteristics to 
have accounted for the results observed, the intake of medications by a majority of our 
participants may have also affected the study outcome despite controlling for medication 
use.  
The assessment of the relationship between leptin with BMI and insulin resistance 
by ethnicity and diabetes status was also conducted. Since leptin levels differed by gender 
in our study, analysis were stratified in line with this difference. Leptin levels were not 
statistically different between males and females, regardless of diabetes status. However, 
with further classification by ethnicity and diabetes status, both Haitian American males 
and females were found to have lower leptin levels compared to African Americans. 
Additionally BMI and insulin resistance were predictors of higher leptin levels only in 
males without T2D.  
The novel finding of our study is the differences shown in chemerin and omentin 
levels and their association with metabolic parameters in two non-Hispanic Black ethnic 
subgroups which has previously not being studied. Other strengths of our study include 
the use of a gender-balanced cohort and for the first time has generated data on 
established and novel adipocytokines particularly in Haitian Americans, a group 
undersampled in diabetes studies.  
Several limitations of this research are important to mention. Failure of our study 
to support some of the hypotheses stated is again believed to be due to the high use of 
medications that have been shown to influence adipocytokines levels by majority of our 
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study subjects. Moreover, we could not control for relevant lifestyle factors such as 
physical activity and detailed dietary factors which also affect adipocytokine levels. The 
cross-sectional design of this study did not allow the determination of temporal and 
causal associations. In addition, the study population is a semi-convenience sample and 
may therefore not be representative of Haitian Americans and African Americans living 
in South Florida. As a result, generalizability to the larger population may be limited. The 
use of surrogate markers such as serum IL-6 concentrations in lieu of IL-6 receptor and 
HOMA-IR instead of the hyperinsulinemic-euglycemic clamp may have also influenced 
the results of this study.  
The current study reveals important differences between Haitian and African 
Americans and further establishes a need for future research to consider these two non-
Hispanic Black ethnic subgroups as unique in order to design effective ethnic-focused 
interventions to reduce the disparities and the high incidence of T2D and its outcomes. A 
better understanding of the role of adipocytokines in the regulation of glucose and lipid 
homeostasis through insulin secretion and signaling is needed. To fully understand the 
ethnic specific effect on the role of adipocytokines, further investigation among Haitian 
and African Americans should be performed. 
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